|
Leader
|
|
|
00000nz a2200037n 45 0 |
|
001
|
|
|
WKP|Q37369291
(VIAF cluster)
(Authority/Source Record)
|
|
003
|
|
|
WKP |
|
005
|
|
|
20241121000154.0 |
|
008
|
|
|
241121nneanz||abbn n and d |
|
035
|
|
|
‡a
(WKP)Q37369291
|
|
024
|
|
|
‡a
0000-0003-0960-6415
‡2
orcid
|
|
024
|
|
|
‡a
7403445073
‡2
scopus
|
|
024
|
|
|
‡a
57198449378
‡2
scopus
|
|
035
|
|
|
‡a
(OCoLC)Q37369291
|
|
046
|
|
|
‡s
19000000
|
|
100
|
0 |
|
‡a
Des R. Richardson
‡c
researcher
‡9
en
|
|
375
|
|
|
‡a
1
‡2
iso5218
|
|
400
|
0 |
|
‡a
Des R Richardson
‡c
investigador
‡9
es
|
|
400
|
0 |
|
‡a
Des R. Richardson
‡c
ricercatore
‡9
it
|
|
400
|
0 |
|
‡a
Des R Richardson
‡c
wetenschapper
‡9
nl
|
|
670
|
|
|
‡a
Author's 2-Acetylpyridine thiosemicarbazones are potent iron chelators and antiproliferative agents: redox activity, iron complexation and characterization of their antitumor activity.
|
|
670
|
|
|
‡a
Author's 24p3 and its receptor: dawn of a new iron age?
|
|
670
|
|
|
‡a
Author's A low-spin iron complex in human melanoma and rat hepatoma cells and a high-spin iron
|
|
670
|
|
|
‡a
Author's A low-spin iron complex in human melanoma and rat hepatoma cells and a high-spin iron(II) complex in rat hepatoma cells.
|
|
670
|
|
|
‡a
Author's A mechanism for overcoming P-glycoprotein-mediated drug resistance: novel combination therapy that releases stored doxorubicin from lysosomes via lysosomal permeabilization using Dp44mT or DpC.
|
|
670
|
|
|
‡a
Author's A Nitric Oxide Storage and Transport System That Protects Activated Macrophages from Endogenous Nitric Oxide Cytotoxicity
|
|
670
|
|
|
‡a
Author's A novel class of thiosemicarbazones show multi-functional activity for the treatment of Alzheimer's disease
|
|
670
|
|
|
‡a
Author's A relationship between glucose metabolism and NO-mediated iron mobilization from cells
|
|
670
|
|
|
‡a
Author's A second melanotransferrin gene
|
|
670
|
|
|
‡a
Author's A second melanotransferrin gene (MTf2) and a novel protein isoform: explanation for the membrane-bound and soluble forms of melanotransferrin?
|
|
670
|
|
|
‡a
Author's Activation of an iron uptake mechanism from transferrin in hepatocytes by small-molecular-weight iron complexes: implications for the pathogenesis of iron-overload disease
|
|
670
|
|
|
‡a
Author's Adenosine monophosphate-activated kinase and its key role in catabolism: structure, regulation, biological activity, and pharmacological activation
|
|
670
|
|
|
‡a
Author's Alkyl substituted 2'-benzoylpyridine thiosemicarbazone chelators with potent and selective anti-neoplastic activity: novel ligands that limit methemoglobin formation
|
|
670
|
|
|
‡a
Author's Amphiphilic hyper-branched co-polymer nanoparticles for the controlled delivery of anti-tumor agents
|
|
670
|
|
|
‡a
Author's Ancestral roles of eukaryotic frataxin: mitochondrial frataxin function and heterologous expression of hydrogenosomal Trichomonas homologues in trypanosomes
|
|
670
|
|
|
‡a
Author's Anthracyclines induce accumulation of iron in ferritin in myocardial and neoplastic cells: inhibition of the ferritin iron mobilization pathway
|
|
670
|
|
|
‡a
Author's Anti-plasmodial activity of aroylhydrazone and thiosemicarbazone iron chelators: effect on erythrocyte membrane integrity, parasite development and the intracellular labile iron pool
|
|
670
|
|
|
‡a
Author's Antitumor activity and mechanism of action of the iron chelator, Dp44mT, against leukemic cells
|
|
670
|
|
|
‡a
Author's Antitumor activity of metal-chelating compound Dp44mT is mediated by formation of a redox-active copper complex that accumulates in lysosomes.
|
|
670
|
|
|
‡a
Author's ATP7A is a novel target of retinoic acid receptor beta2 in neuroblastoma cells.
|
|
670
|
|
|
‡a
Author's Beta-thalassaemia: emergence of new and improved iron chelators for treatment.
|
|
670
|
|
|
‡a
Author's Biochemical and spectroscopic studies of human melanotransferrin
|
|
670
|
|
|
‡a
Author's Biochemical and spectroscopic studies of human melanotransferrin (MTf): electron-paramagnetic resonance evidence for a difference between the iron-binding site of MTf and other transferrins.
|
|
670
|
|
|
‡a
Author's Biochemistry of cardiomyopathy in the mitochondrial disease Friedreich's ataxia.
|
|
670
|
|
|
‡a
Author's Biphasic effects of l-ascorbate on the tumoricidal activity of non-thermal plasma against malignant mesothelioma cells.
|
|
670
|
|
|
‡a
Author's Bonnie and Clyde: Vitamin C and iron are partners in crime in iron deficiency anaemia and its potential role in the elderly.
|
|
670
|
|
|
‡a
Author's Can we target the α2-macroglobulin-hepcidin interaction to treat pathologic hypoferremia?
|
|
670
|
|
|
‡a
Author's Cancer cell iron metabolism and the development of potent iron chelators as anti-tumour agents.
|
|
670
|
|
|
‡a
Author's Cellular iron depletion and the mechanisms involved in the iron-dependent regulation of the growth arrest and DNA damage family of genes
|
|
670
|
|
|
‡a
Author's Cellular iron depletion stimulates the JNK and p38 MAPK signaling transduction pathways, dissociation of ASK1-thioredoxin, and activation of ASK1.
|
|
670
|
|
|
‡a
Author's Cellular iron uptake, trafficking and metabolism: Key molecules and mechanisms and their roles in disease
|
|
670
|
|
|
‡a
Author's Cellular uptake of the antitumor agent Dp44mT occurs via a carrier/receptor-mediated mechanism.
|
|
670
|
|
|
‡a
Author's Chaperone turns gatekeeper: PCBP2 and DMT1 form an iron-transport pipeline
|
|
670
|
|
|
‡a
Author's Chelators at the cancer coalface: desferrioxamine to Triapine and beyond.
|
|
670
|
|
|
‡a
Author's Chelators to the Rescue: Different Horses for Different Courses!
|
|
670
|
|
|
‡a
Author's Cloning of the ferrireductase that may be involved in iron transport in the small intestine: revisiting Crane's controversial oxidoreductase
|
|
670
|
|
|
‡a
Author's Comparison of clinically used and experimental iron chelators for protection against oxidative stress-induced cellular injury.
|
|
670
|
|
|
‡a
Author's Competing pathways of iron chelation: angiogenesis or anti-tumor activity: targeting different molecules to induce specific effects
|
|
670
|
|
|
‡a
Author's Complexes of cytotoxic chelators from the dipyridyl ketone isonicotinoyl hydrazone (HPKIH) analogues
|
|
670
|
|
|
‡a
Author's Conjugates of desferrioxamine B
|
|
670
|
|
|
‡a
Author's Conjugates of desferrioxamine B (DFOB) with derivatives of adamantane or with orally available chelators as potential agents for treating iron overload
|
|
670
|
|
|
‡a
Author's Copper and conquer: copper complexes of di-2-pyridylketone thiosemicarbazones as novel anti-cancer therapeutics.
|
|
670
|
|
|
‡a
Author's Copper that cancer with lysosomal love!
|
|
670
|
|
|
‡a
Author's Correction: N-myc Downstream Regulated 1
|
|
670
|
|
|
‡a
Author's Correction: N-myc Downstream Regulated 1 (NDRG1) Is Regulated by Eukaryotic Initiation Factor 3a (eIF3a) during Cellular Stress Caused by Iron Depletion
|
|
670
|
|
|
‡a
Author's Coupling of the polyamine and iron metabolism pathways in the regulation of proliferation: Mechanistic links to alterations in key polyamine biosynthetic and catabolic enzymes
|
|
670
|
|
|
‡a
Author's Crystal and molecular structure of 2-hydroxy-1-naphthaldehyde isonicotinoyl hydrazone (NIH) and its iron(III) complex: an iron chelator with anti-tumour activity
|
|
670
|
|
|
‡a
Author's Cytosolic phospholipase A2α sustains pAKT, pERK and AR levels in PTEN-null/mutated prostate cancer cells
|
|
670
|
|
|
‡a
Author's Cytotoxic iron chelators: characterization of the structure, solution chemistry and redox activity of ligands and iron complexes of the di-2-pyridyl ketone isonicotinoyl hydrazone (HPKIH) analogues
|
|
670
|
|
|
‡a
Author's Deferiprone: greater efficacy at depleting myocardial than hepatic iron?
|
|
670
|
|
|
‡a
Author's Design, synthesis, and characterization of new iron chelators with anti-proliferative activity: structure-activity relationships of novel thiohydrazone analogues.
|
|
670
|
|
|
‡a
Author's Design, synthesis, and characterization of novel iron chelators: structure-activity relationships of the 2-benzoylpyridine thiosemicarbazone series and their 3-nitrobenzoyl analogues as potent antitumor agents.
|
|
670
|
|
|
‡a
Author's Development and validation of HPLC-DAD methods for the analysis of two novel iron chelators with potent anti-cancer activity
|
|
670
|
|
|
‡a
Author's Development of an LC-MS/MS method for analysis of interconvertible Z/E isomers of the novel anticancer agent, Bp4eT.
|
|
670
|
|
|
‡a
Author's Development of iron chelators to treat iron overload disease and their use as experimental tools to probe intracellular iron metabolism
|
|
670
|
|
|
‡a
Author's Development of novel aroylhydrazone ligands for iron chelation therapy: 2-pyridylcarboxaldehyde isonicotinoyl hydrazone analogs
|
|
670
|
|
|
‡a
Author's Development of potential iron chelators for the treatment of Friedreich's ataxia: ligands that mobilize mitochondrial iron
|
|
670
|
|
|
‡a
Author's Di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT) overcomes multidrug resistance by a novel mechanism involving the hijacking of lysosomal P-glycoprotein (Pgp).
|
|
670
|
|
|
‡a
Author's Differential effects on cellular iron metabolism of the physiologically relevant diatomic effector molecules, NO and CO, that bind iron
|
|
670
|
|
|
‡a
Author's Differential regulation of the Menkes and Wilson disease copper transporters by hormones: an integrated model of metal transport in the placenta
|
|
670
|
|
|
‡a
Author's Differential targeting of the cyclin-dependent kinase inhibitor, p21CIP1/WAF1, by chelators with anti-proliferative activity in a range of tumor cell-types
|
|
670
|
|
|
‡a
Author's Dipyridyl Thiosemicarbazone Chelators with Potent and Selective Antitumor Activity Form Iron Complexes with Redox Activity
|
|
670
|
|
|
‡a
Author's Does free extracellular iron exist in haemochromatosis and other pathologies, and is it redox active?
|
|
670
|
|
|
‡a
Author's Dp44mT targets the AKT, TGF-β and ERK pathways via the metastasis suppressor NDRG1 in normal prostate epithelial cells and prostate cancer cells.
|
|
670
|
|
|
‡a
Author's Duodenal cytochrome b (DCYTB) in iron metabolism: an update on function and regulation.
|
|
670
|
|
|
‡a
Author's Effect of pyridoxal isonicotinoyl hydrazone and other hydrazones on iron release from macrophages, reticulocytes and hepatocytes
|
|
670
|
|
|
‡a
Author's Effect of the piperazine unit and metal-binding site position on the solubility and anti-proliferative activity of ruthenium(II)- and osmium(II)- arene complexes of isomeric indolo[3,2-c]quinoline-piperazine hybrids.
|
|
670
|
|
|
‡a
Author's Effects of nitrogen monoxide and carbon monoxide on molecular and cellular iron metabolism: mirror-image effector molecules that target iron
|
|
670
|
|
|
‡a
Author's Elucidation of the mechanism of mitochondrial iron loading in Friedreich's ataxia by analysis of a mouse mutant
|
|
670
|
|
|
‡a
Author's en scientific article
|
|
670
|
|
|
‡a
Author's Endoplasmic reticulum protein 29
|
|
670
|
|
|
‡a
Author's Endoplasmic reticulum protein 29 (ERp29): An emerging role in cancer
|
|
670
|
|
|
‡a
Author's Endoplasmic reticulum protein 29 regulates epithelial cell integrity during the mesenchymal-epithelial transition in breast cancer cells
|
|
670
|
|
|
‡a
Author's ERp29 induces breast cancer cell growth arrest and survival through modulation of activation of p38 and upregulation of ER stress protein p58IPK
|
|
670
|
|
|
‡a
Author's Erythroid differentiation and protoporphyrin IX down-regulate frataxin expression in Friend cells: characterization of frataxin expression compared to molecules involved in iron metabolism and hemoglobinization
|
|
670
|
|
|
‡a
Author's Examination of the distribution of the transferrin homologue, melanotransferrin (tumour antigen p97), in mouse and human.
|
|
670
|
|
|
‡a
Author's Examination of the mechanism of action of nitrogen monoxide on iron uptake from transferrin
|
|
670
|
|
|
‡a
Author's Examination of the mechanism(s) involved in doxorubicin-mediated iron accumulation in ferritin: studies using metabolic inhibitors, protein synthesis inhibitors, and lysosomotropic agents
|
|
670
|
|
|
‡a
Author's Expanding horizons in iron chelation and the treatment of cancer: role of iron in the regulation of ER stress and the epithelial-mesenchymal transition.
|
|
670
|
|
|
‡a
Author's Exploiting Cancer Metal Metabolism using Anti-Cancer Metal-Binding Agents.
|
|
670
|
|
|
‡a
Author's Exploring the anti-cancer activity of novel thiosemicarbazones generated through the combination of retro-fragments: dissection of critical structure-activity relationships
|
|
670
|
|
|
‡a
Author's Fixing frataxin: 'ironing out' the metabolic defect in Friedreich's ataxia
|
|
670
|
|
|
‡a
Author's Four cytotoxic N4-substituted thiosemicarbazones derived from 2-hydroxynaphthalene-1-carboxaldehyde
|
|
670
|
|
|
‡a
Author's Frataxin, a molecule of mystery: trading stability for function in its iron-binding site
|
|
670
|
|
|
‡a
Author's Frataxin and the molecular mechanism of mitochondrial iron-loading in Friedreich's ataxia
|
|
670
|
|
|
‡a
Author's Frataxin: its role in iron metabolism and the pathogenesis of Friedreich's ataxia.
|
|
670
|
|
|
‡a
Author's Future of toxicology--iron chelators and differing modes of action and toxicity: the changing face of iron chelation therapy
|
|
670
|
|
|
‡a
Author's Gene of the month. AMP kinase (PRKAA1).
|
|
670
|
|
|
‡a
Author's Gene of the month: BECN1.
|
|
670
|
|
|
‡a
Author's Gene of the month: Interleukin 6 (IL-6).
|
|
670
|
|
|
‡a
Author's Generation and characterization of transgenic mice hyper-expressing melanoma tumour antigen p97
|
|
670
|
|
|
‡a
Author's Generation and characterization of transgenic mice hyper-expressing melanoma tumour antigen p97 (Melanotransferrin): no overt alteration in phenotype.
|
|
670
|
|
|
‡a
Author's Glucose Modulation Induces Lysosome Formation and Increases Lysosomotropic Drug Sequestration via the P-Glycoprotein Drug Transporter.
|
|
670
|
|
|
‡a
Author's Glucose modulation induces reactive oxygen species and increases P-glycoprotein-mediated multidrug resistance to chemotherapeutics.
|
|
670
|
|
|
‡a
Author's Growth arrest and DNA damage-45 alpha
|
|
670
|
|
|
‡a
Author's Growth arrest and DNA damage-45 alpha (GADD45alpha).
|
|
670
|
|
|
‡a
Author's Growth of human tumor cell lines in transferrin-free, low-iron medium
|
|
670
|
|
|
‡a
Author's Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)
|
|
670
|
|
|
‡a
Author's Halogenated 2'-benzoylpyridine thiosemicarbazone
|
|
670
|
|
|
‡a
Author's Halogenated 2'-benzoylpyridine thiosemicarbazone (XBpT) chelators with potent and selective anti-neoplastic activity: relationship to intracellular redox activity
|
|
670
|
|
|
‡a
Author's Hepcidin, show some self-control! How the hormone of iron metabolism regulates its own expression.
|
|
670
|
|
|
‡a
Author's Hepcidin, the hormone of iron metabolism, is bound specifically to alpha-2-macroglobulin in blood.
|
|
670
|
|
|
‡a
Author's Heterocyclic dithiocarbazate iron chelators: Fe coordination chemistry and biological activity.
|
|
670
|
|
|
‡a
Author's HPLC methods for determination of two novel thiosemicarbazone anti-cancer drugs
|
|
670
|
|
|
‡a
Author's HPLC methods for determination of two novel thiosemicarbazone anti-cancer drugs (N4mT and Dp44mT) in plasma and their application to in vitro plasma stability of these agents
|
|
670
|
|
|
‡a
Author's Hydrazone chelators for the treatment of iron overload disorders: iron coordination chemistry and biological activity
|
|
670
|
|
|
‡a
Author's Identification and characterization of thiosemicarbazones with antifungal and antitumor effects: cellular iron chelation mediating cytotoxic activity.
|
|
670
|
|
|
‡a
Author's Identification of a mechanism of iron uptake by cells which is stimulated by hydroxyl radicals generated via the iron-catalysed Haber-Weiss reaction
|
|
670
|
|
|
‡a
Author's Identification of differential anti-neoplastic activity of copper bis(thiosemicarbazones) that is mediated by intracellular reactive oxygen species generation and lysosomal membrane permeabilization
|
|
670
|
|
|
‡a
Author's Identification of differential phosphorylation and sub-cellular localization of the metastasis suppressor, NDRG1.
|
|
670
|
|
|
‡a
Author's Identification of distinct changes in gene expression after modulation of melanoma tumor antigen p97 (melanotransferrin) in multiple models in vitro and in vivo
|
|
670
|
|
|
‡a
Author's Identification of in vitro metabolites of the novel anti-tumor thiosemicarbazone, DpC, using ultra-high performance liquid chromatography–quadrupole-time-of-flight mass spectrometry
|
|
670
|
|
|
‡a
Author's Identification of nonferritin mitochondrial iron deposits in a mouse model of Friedreich ataxia
|
|
670
|
|
|
‡a
Author's In Vitro Characterization of the Pharmacological Properties of the Anti-Cancer Chelator, Bp4eT, and Its Phase I Metabolites
|
|
670
|
|
|
‡a
Author's Interferon-gamma and lipopolysaccharide regulate the expression of Nramp2 and increase the uptake of iron from low relative molecular mass complexes by macrophages
|
|
670
|
|
|
‡a
Author's Interplay of the iron-regulated metastasis suppressor NDRG1 with epidermal growth factor receptor
|
|
670
|
|
|
‡a
Author's Interplay of the iron-regulated metastasis suppressor NDRG1 with epidermal growth factor receptor (EGFR) and oncogenic signaling.
|
|
670
|
|
|
‡a
Author's Investigating biological activity spectrum for novel quinoline analogues
|
|
670
|
|
|
‡a
Author's Investigating the activity of 2-substituted alkyl-6-(2,5-dioxopyrrolidin-1-yl)hexanoates as skin penetration enhancers
|
|
670
|
|
|
‡a
Author's Investigating the anti-proliferative activity of styrylazanaphthalenes and azanaphthalenediones
|
|
670
|
|
|
‡a
Author's Investigating the antiproliferative activity of quinoline-5,8-diones and styrylquinolinecarboxylic acids on tumor cell lines.
|
|
670
|
|
|
‡a
Author's Investigating the spectrum of biological activity of ring-substituted salicylanilides and carbamoylphenylcarbamates.
|
|
670
|
|
|
‡a
Author's Investigation of substituted 6-aminohexanoates as skin penetration enhancers
|
|
670
|
|
|
‡a
Author's Iron and gallium increase iron uptake from transferrin by human melanoma cells: further examination of the ferric ammonium citrate-activated iron uptake process
|
|
670
|
|
|
‡a
Author's Iron and neoplasia: serum transferrin receptor and ferritin in prostate cancer
|
|
670
|
|
|
‡a
Author's Iron catalysed assembly of an asymmetric mixed-ligand triple helicate
|
|
670
|
|
|
‡a
Author's Iron chelation and regulation of the cell cycle: 2 mechanisms of posttranscriptional regulation of the universal cyclin-dependent kinase inhibitor p21CIP1/WAF1 by iron depletion
|
|
670
|
|
|
‡a
Author's Iron chelation by clinically relevant anthracyclines: alteration in expression of iron-regulated genes and atypical changes in intracellular iron distribution and trafficking.
|
|
670
|
|
|
‡a
Author's Iron chelation: deciphering novel molecular targets for cancer therapy. The tip of the iceberg of a web of iron-regulated molecules
|
|
670
|
|
|
‡a
Author's Iron chelation: inhibition of key signaling pathways in the induction of the epithelial mesenchymal transition in pancreatic cancer and other tumors
|
|
670
|
|
|
‡a
Author's Iron chelation regulates cyclin D1 expression via the proteasome: a link to iron deficiency-mediated growth suppression
|
|
670
|
|
|
‡a
Author's Iron chelator-mediated alterations in gene expression: identification of novel iron-regulated molecules that are molecular targets of hypoxia-inducible factor-1 alpha and p53.
|
|
670
|
|
|
‡a
Author's Iron chelators as therapeutic agents for the treatment of cancer.
|
|
670
|
|
|
‡a
Author's Iron Chelators: Development of Novel Compounds with High and Selective Anti-Tumour Activity
|
|
670
|
|
|
‡a
Author's Iron chelators for the treatment of iron overload disease: relationship between structure, redox activity, and toxicity.
|
|
670
|
|
|
‡a
Author's Iron chelators of the di-2-pyridylketone thiosemicarbazone and 2-benzoylpyridine thiosemicarbazone series inhibit HIV-1 transcription: identification of novel cellular targets--iron, cyclin-dependent kinase (CDK) 2, and CDK9
|
|
670
|
|
|
‡a
Author's Iron chelators of the dipyridylketone thiosemicarbazone class: precomplexation and transmetalation effects on anticancer activity.
|
|
670
|
|
|
‡a
Author's Iron chelators with high antiproliferative activity up-regulate the expression of a growth inhibitory and metastasis suppressor gene: a link between iron metabolism and proliferation
|
|
670
|
|
|
‡a
Author's Iron Export through the Transporter Ferroportin 1 Is Modulated by the Iron Chaperone PCBP2.
|
|
670
|
|
|
‡a
Author's Iron trafficking in the mitochondrion: novel pathways revealed by disease.
|
|
670
|
|
|
‡a
Author's Iron uptake and metabolism in the new millennium.
|
|
670
|
|
|
‡a
Author's Ironing out the role of the cyclin-dependent kinase inhibitor, p21 in cancer: Novel iron chelating agents to target p21 expression and activity.
|
|
670
|
|
|
‡a
Author's Kinetic studies on the oxidation of oxyhemoglobin by biologically active iron thiosemicarbazone complexes: relevance to iron-chelator-induced methemoglobinemia.
|
|
670
|
|
|
‡a
Author's Kinetico-mechanistic studies on methemoglobin generation by biologically active thiosemicarbazone iron(III) complexes
|
|
670
|
|
|
‡a
Author's Laying Down a Solid "Iron Foundation": Professor Erica Baker
|
|
670
|
|
|
‡a
Author's LC-MS/MS identification of the principal in vitro and in vivo phase I metabolites of the novel thiosemicarbazone anti-cancer drug, Bp4eT.
|
|
670
|
|
|
‡a
Author's Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come.
|
|
670
|
|
|
‡a
Author's Lysosomal membrane stability plays a major role in the cytotoxic activity of the anti-proliferative agent, di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT).
|
|
670
|
|
|
‡a
Author's Making a case for albumin – a highly promising drug-delivery system.
|
|
670
|
|
|
‡a
Author's Mechanism of the induction of endoplasmic reticulum stress by the anti-cancer agent, di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT): Activation of PERK/eIF2α, IRE1α, ATF6 and calmodulin kinase
|
|
670
|
|
|
‡a
Author's Melanotransferrin: search for a function.
|
|
670
|
|
|
‡a
Author's Membrane transport and intracellular sequestration of novel thiosemicarbazone chelators for the treatment of cancer.
|
|
670
|
|
|
‡a
Author's Metal chelation
|
|
670
|
|
|
‡a
Author's Metals and metastasis: Exploiting the role of metals in cancer metastasis to develop novel anti-metastatic agents.
|
|
670
|
|
|
‡a
Author's Metastasis suppressor, NDRG1, mediates its activity through signaling pathways and molecular motors.
|
|
670
|
|
|
‡a
Author's Methemoglobin formation by triapine, di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone (Dp44mT), and other anticancer thiosemicarbazones: identification of novel thiosemicarbazones and therapeutics that prevent this effect
|
|
670
|
|
|
‡a
Author's Mitochondrial dysfunction in the neuro-degenerative and cardio-degenerative disease, Friedreich's ataxia.
|
|
670
|
|
|
‡a
Author's Mitochondrial iron metabolism and sideroblastic anemia
|
|
670
|
|
|
‡a
Author's Mitochondrial mayhem: the mitochondrion as a modulator of iron metabolism and its role in disease
|
|
670
|
|
|
‡a
Author's Mobilization of iron from neoplastic cells by some iron chelators is an energy-dependent process
|
|
670
|
|
|
‡a
Author's Molecular Alterations in a Mouse Cardiac Model of Friedreich Ataxia: An Impaired Nrf2 Response Mediated via Upregulation of Keap1 and Activation of the Gsk3β Axis.
|
|
670
|
|
|
‡a
Author's Molecular and functional alterations in a mouse cardiac model of Friedreich ataxia: activation of the integrated stress response, eIF2α phosphorylation, and the induction of downstream targets.
|
|
670
|
|
|
‡a
Author's Molecular functions of the iron-regulated metastasis suppressor, NDRG1, and its potential as a molecular target for cancer therapy.
|
|
670
|
|
|
‡a
Author's Molecular pharmacology of ABCG2 and its role in chemoresistance
|
|
670
|
|
|
‡a
Author's Multiple effects of iron chelators on molecules controlling cell cycle progression
|
|
670
|
|
|
‡a
Author's Mysteries of the transferrin-transferrin receptor 1 interaction uncovered
|
|
670
|
|
|
‡a
Author's N-myc downstream regulated 1
|
|
670
|
|
|
‡a
Author's N-myc downstream regulated 1 (NDRG1) is regulated by eukaryotic initiation factor 3a (eIF3a) during cellular stress caused by iron depletion.
|
|
670
|
|
|
‡a
Author's NDRG1 as a molecular target to inhibit the epithelial-mesenchymal transition: the case for developing inhibitors of metastasis
|
|
670
|
|
|
‡a
Author's Nitrogen monoxide
|
|
670
|
|
|
‡a
Author's Nitrogen monoxide activates iron regulatory protein 1 RNA-binding activity by two possible mechanisms: effect on the [4Fe-4S] cluster and iron mobilization from cells
|
|
670
|
|
|
‡a
Author's Nitrogen monoxide decreases iron uptake from transferrin but does not mobilise iron from prelabelled neoplastic cells
|
|
670
|
|
|
‡a
Author's Nitrogen monoxide (no) and glucose: unexpected links between energy metabolism and no-mediated iron mobilization from cells
|
|
670
|
|
|
‡a
Author's Nitrogen monoxide (NO)-mediated iron release from cells is linked to NO-induced glutathione efflux via multidrug resistance-associated protein 1.
|
|
670
|
|
|
‡a
Author's Non-thermal plasma induces a stress response in mesothelioma cells resulting in increased endocytosis, lysosome biogenesis and autophagy.
|
|
670
|
|
|
‡a
Author's Novel and potent anti-tumor and anti-metastatic di-2-pyridylketone thiosemicarbazones demonstrate marked differences in pharmacology between the first and second generation lead agents.
|
|
670
|
|
|
‡a
Author's Novel aroylhydrazone and thiosemicarbazone iron chelators with anti-malarial activity against chloroquine-resistant and -sensitive parasites
|
|
670
|
|
|
‡a
Author's Novel chelators based on adamantane-derived semicarbazones and hydrazones that target multiple hallmarks of Alzheimer's disease
|
|
670
|
|
|
‡a
Author's Novel chelators for cancer treatment: where are we now?
|
|
670
|
|
|
‡a
Author's Novel chelators for central nervous system disorders that involve alterations in the metabolism of iron and other metal ions.
|
|
670
|
|
|
‡a
Author's Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment.
|
|
670
|
|
|
‡a
Author's Novel diaroylhydrazine ligands as iron chelators: coordination chemistry and biological activity.
|
|
670
|
|
|
‡a
Author's Novel "hybrid" iron chelators derived from aroylhydrazones and thiosemicarbazones demonstrate selective antiproliferative activity against tumor cells
|
|
670
|
|
|
‡a
Author's Novel Mechanism of Cytotoxicity for the Selective Selenosemicarbazone, 2-Acetylpyridine 4,4-Dimethyl-3-selenosemicarbazone (Ap44mSe): Lysosomal Membrane Permeabilization
|
|
670
|
|
|
‡a
Author's Novel second-generation di-2-pyridylketone thiosemicarbazones show synergism with standard chemotherapeutics and demonstrate potent activity against lung cancer xenografts after oral and intravenous administration in vivo.
|
|
670
|
|
|
‡a
Author's Novel thiosemicarbazone iron chelators induce up-regulation and phosphorylation of the metastasis suppressor N-myc down-stream regulated gene 1: a new strategy for the treatment of pancreatic cancer
|
|
670
|
|
|
‡a
Author's Novel Thiosemicarbazones Inhibit Lysine-Rich Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 (CEACAM1) Coisolated (LYRIC) and the LYRIC-Induced Epithelial-Mesenchymal Transition via Upregulation of N-Myc Downstream-Regulated Gene 1 (NDRG1)
|
|
670
|
|
|
‡a
Author's Novel thiosemicarbazones of the ApT and DpT series and their copper complexes: identification of pronounced redox activity and characterization of their antitumor activity.
|
|
670
|
|
|
‡a
Author's Novel thiosemicarbazones regulate the signal transducer and activator of transcription 3 (STAT3) pathway: inhibition of constitutive and interleukin 6-induced activation by iron depletion
|
|
670
|
|
|
‡a
Author's P-glycoprotein mediates drug resistance via a novel mechanism involving lysosomal sequestration.
|
|
670
|
|
|
‡a
Author's PCTH: a novel orally active chelator of the aroylhydrazone class that induces iron excretion from mice.
|
|
670
|
|
|
‡a
Author's PGRMC1 regulation by phosphorylation: potential new insights in controlling biological activity!
|
|
670
|
|
|
‡a
Author's Pharmacological targeting of mitochondria in cancer stem cells: An ancient organelle at the crossroad of novel anti-cancer therapies
|
|
670
|
|
|
‡a
Author's Pharmacological targeting of the integrated protein kinase B, phosphatase and tensin homolog deleted on chromosome 10, and transforming growth factor-beta pathways in prostate cancer.
|
|
670
|
|
|
‡a
Author's Potent antimycobacterial activity of the pyridoxal isonicotinoyl hydrazone analog 2-pyridylcarboxaldehyde isonicotinoyl hydrazone: a lipophilic transport vehicle for isonicotinic acid hydrazide.
|
|
670
|
|
|
‡a
Author's Potent antitumor activity of novel iron chelators derived from di-2-pyridylketone isonicotinoyl hydrazone involves fenton-derived free radical generation
|
|
670
|
|
|
‡a
Author's Potent iron chelators increase the mRNA levels of the universal cyclin-dependent kinase inhibitor p21(CIP1/WAF1), but paradoxically inhibit its translation: a potential mechanism of cell cycle dysregulation
|
|
670
|
|
|
‡a
Author's Potential of iron chelators as effective antiproliferative agents
|
|
670
|
|
|
‡a
Author's Protection against hydrogen peroxide-mediated cytotoxicity in Friedreich's ataxia fibroblasts using novel iron chelators of the 2-pyridylcarboxaldehyde isonicotinoyl hydrazone class.
|
|
670
|
|
|
‡a
Author's Proteolytic cleavage and truncation of NDRG1 in human prostate cancer cells, but not normal prostate epithelial cells.
|
|
670
|
|
|
‡a
Author's Proteomic analysis of hearts from frataxin knockout mice: marked rearrangement of energy metabolism, a response to cellular stress and altered expression of proteins involved in cell structure, motility and metabolism
|
|
670
|
|
|
‡a
Author's Proton transfer and ferredoxin I: the secrets of redox-driven proton transfer between solvent and a buried iron-sulphur cluster.
|
|
670
|
|
|
‡a
Author's Pyridoxal isonicotinoyl hydrazone and analogues. Study of their stability in acidic, neutral and basic aqueous solutions by ultraviolet-visible spectrophotometry
|
|
670
|
|
|
‡a
Author's Redox cycling metals: Pedaling their roles in metabolism and their use in the development of novel therapeutics
|
|
670
|
|
|
‡a
Author's Regulation and control of nitric oxide
|
|
670
|
|
|
‡a
Author's Regulation and control of nitric oxide (NO) in macrophages: Protecting the "professional killer cell" from its own cytotoxic arsenal via MRP1 and GSTP1.
|
|
670
|
|
|
‡a
Author's Resistance to the antineoplastic agent gallium nitrate results in marked alterations in intracellular iron and gallium trafficking: identification of novel intermediates
|
|
670
|
|
|
‡a
Author's Roads to melanoma: Key pathways and emerging players in melanoma progression and oncogenic signaling
|
|
670
|
|
|
‡a
Author's Role of ceruloplasmin and ascorbate in cellular iron release
|
|
670
|
|
|
‡a
Author's Role of glutaredoxin1 and glutathione in regulating the activity of the copper-transporting P-type ATPases, ATP7A and ATP7B.
|
|
670
|
|
|
‡a
Author's Siderocalin/Lcn2/NGAL/24p3 does not drive apoptosis through gentisic acid mediated iron withdrawal in hematopoietic cell lines
|
|
670
|
|
|
‡a
Author's Simultaneous determination of the novel thiosemicarbazone anti-cancer agent, Bp4eT, and its main phase I metabolites in plasma: application to a pilot pharmacokinetic study in rats
|
|
670
|
|
|
‡a
Author's Structure-Activity Relationships of Di-2-pyridylketone, 2-Benzoylpyridine, and 2-Acetylpyridine Thiosemicarbazones for Overcoming Pgp-Mediated Drug Resistance.
|
|
670
|
|
|
‡a
Author's Structure-activity relationships of novel iron chelators for the treatment of iron overload disease: the methyl pyrazinylketone isonicotinoyl hydrazone series.
|
|
670
|
|
|
‡a
Author's Structure-activity studies of 4-phenyl-substituted 2'-benzoylpyridine thiosemicarbazones with potent and selective anti-tumour activity.
|
|
670
|
|
|
‡a
Author's Sustained expression of heme oxygenase-1 alters iron homeostasis in nonerythroid cells.
|
|
670
|
|
|
‡a
Author's Synthesis and biological evaluation of 2-benzoylpyridine thiosemicarbazones in a dimeric system: structure-activity relationship studies on their anti-proliferative and iron chelation efficacy.
|
|
670
|
|
|
‡a
Author's Synthesis and biological evaluation of substituted 2-benzoylpyridine thiosemicarbazones: novel structure-activity relationships underpinning their anti-proliferative and chelation efficacy
|
|
670
|
|
|
‡a
Author's Synthesis and characterization of quinoline-based thiosemicarbazones and correlation of cellular iron-binding efficacy to anti-tumor efficacy
|
|
670
|
|
|
‡a
Author's Synthesis, Characterization, and in Vitro Anticancer Activity of Copper and Zinc Bis(Thiosemicarbazone) Complexes
|
|
670
|
|
|
‡a
Author's Synthetic and natural products as iron chelators
|
|
670
|
|
|
‡a
Author's Tabibi Sabbu
|
|
670
|
|
|
‡a
Author's Targeting autophagy in antitumor agent design: furthering the 'lysosomal love' strategy.
|
|
670
|
|
|
‡a
Author's Targeting cancer by binding iron: Dissecting cellular signaling pathways
|
|
670
|
|
|
‡a
Author's Targeting Oncogenic NF-κB Signaling with Redox-Active Agents for Cancer Treatment
|
|
670
|
|
|
‡a
Author's Targeting the Metastasis Suppressor, N-Myc Downstream Regulated Gene-1, with Novel Di-2-Pyridylketone Thiosemicarbazones: Suppression of Tumor Cell Migration and Cell-Collagen Adhesion by Inhibiting Focal Adhesion Kinase/Paxillin Signaling.
|
|
670
|
|
|
‡a
Author's Targeting the metastasis suppressor, NDRG1, using novel iron chelators: regulation of stress fiber-mediated tumor cell migration via modulation of the ROCK1/pMLC2 signaling pathway
|
|
670
|
|
|
‡a
Author's The active role of vitamin C in mammalian iron metabolism: much more than just enhanced iron absorption!
|
|
670
|
|
|
‡a
Author's The anticancer agent di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT) overcomes prosurvival autophagy by two mechanisms: persistent induction of autophagosome synthesis and impairment of lysosomal integrity.
|
|
670
|
|
|
‡a
Author's The Anticancer Agent, Di-2-Pyridylketone 4,4-Dimethyl-3-Thiosemicarbazone (Dp44mT), Up-Regulates the AMPK-Dependent Energy Homeostasis Pathway in Cancer Cells
|
|
670
|
|
|
‡a
Author's The biogenesis of [Fe-S] clusters: the role of the unorthodox ABC ATPase, SufC, and the wider implications for understanding iron metabolism
|
|
670
|
|
|
‡a
Author's The cardioprotective effect of the iron chelator dexrazoxane
|
|
670
|
|
|
‡a
Author's The cardioprotective effect of the iron chelator dexrazoxane (ICRF-187) on anthracycline-mediated cardiotoxicity.
|
|
670
|
|
|
‡a
Author's The controversial role of deferiprone in the treatment of thalassemia.
|
|
670
|
|
|
‡a
Author's The double-edged nature of using genetic databases: melanotransferrin genes and transcripts
|
|
670
|
|
|
‡a
Author's The effect of desferrioxamine and ferric ammonium citrate on the uptake of iron by the membrane iron-binding component of human melanoma cells
|
|
670
|
|
|
‡a
Author's The effect of intracellular iron concentration and nitrogen monoxide on Nramp2 expression and non-transferrin-bound iron uptake
|
|
670
|
|
|
‡a
Author's The effect of potent iron chelators on the regulation of p53: examination of the expression, localization and DNA-binding activity of p53 and the transactivation of WAF1.
|
|
670
|
|
|
‡a
Author's The emerging role of progesterone receptor membrane component 1 (PGRMC1) in cancer biology.
|
|
670
|
|
|
‡a
Author's The evolution of iron chelators for the treatment of iron overload disease and cancer.
|
|
670
|
|
|
‡a
Author's The function of melanotransferrin: a role in melanoma cell proliferation and tumorigenesis.
|
|
670
|
|
|
‡a
Author's The ins and outs of mitochondrial iron-loading: the metabolic defect in Friedreich's ataxia.
|
|
670
|
|
|
‡a
Author's The iron chaperone poly(rC)-binding protein 2 forms a metabolon with the heme oxygenase 1/cytochrome P450 reductase complex for heme catabolism and iron transfer
|
|
670
|
|
|
‡a
Author's The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action
|
|
670
|
|
|
‡a
Author's The iron chelators Dp44mT and DFO inhibit TGF-β-induced epithelial-mesenchymal transition via up-regulation of N-Myc downstream-regulated gene 1
|
|
670
|
|
|
‡a
Author's The iron chelators Dp44mT and DFO inhibit TGF-β-induced epithelial-mesenchymal transition via up-regulation of N-Myc downstream-regulated gene 1 (NDRG1).
|
|
670
|
|
|
‡a
Author's The iron complex of Dp44mT is redox-active and induces hydroxyl radical formation: an EPR study.
|
|
670
|
|
|
‡a
Author's The iron-regulated metastasis suppressor, Ndrg-1: identification of novel molecular targets
|
|
670
|
|
|
‡a
Author's The iron-regulated metastasis suppressor NDRG1 targets NEDD4L, PTEN, and SMAD4 and inhibits the PI3K and Ras signaling pathways
|
|
670
|
|
|
‡a
Author's The lure of a LYR: The logistics of iron sulfur cluster delivery
|
|
670
|
|
|
‡a
Author's The mechanism of nitrogen monoxide
|
|
670
|
|
|
‡a
Author's The mechanism of nitrogen monoxide (NO)-mediated iron mobilization from cells. NO intercepts iron before incorporation into ferritin and indirectly mobilizes iron from ferritin in a glutathione-dependent manner
|
|
670
|
|
|
‡a
Author's The mechanistic role of chemically diverse metal ions in the induction of autophagy
|
|
670
|
|
|
‡a
Author's The medicinal chemistry of novel iron chelators for the treatment of cancer.
|
|
670
|
|
|
‡a
Author's The melanoma tumor antigen, melanotransferrin (p97): a 25-year hallmark--from iron metabolism to tumorigenesis.
|
|
670
|
|
|
‡a
Author's The Metastasis Suppressor, N-MYC Downstream-regulated Gene-1 (NDRG1), Down-regulates the ErbB Family of Receptors to Inhibit Downstream Oncogenic Signaling Pathways
|
|
670
|
|
|
‡a
Author's The metastasis suppressor, N-myc downstream-regulated gene 1 (NDRG1), inhibits stress-induced autophagy in cancer cells.
|
|
670
|
|
|
‡a
Author's The metastasis suppressor, N-myc downstream regulated gene 1 (NDRG1), upregulates p21 via p53-independent mechanisms.
|
|
670
|
|
|
‡a
Author's The metastasis suppressor, Ndrg-1: a new ally in the fight against cancer
|
|
670
|
|
|
‡a
Author's The metastasis suppressor, NDRG1, inhibits "stemness" of colorectal cancer via down-regulation of nuclear β-catenin and CD44.
|
|
670
|
|
|
‡a
Author's The metastasis suppressor NDRG1 modulates the phosphorylation and nuclear translocation of β-catenin through mechanisms involving FRAT1 and PAK4.
|
|
670
|
|
|
‡a
Author's The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cells
|
|
670
|
|
|
‡a
Author's The nitric oxide-iron interplay in mammalian cells: transport and storage of dinitrosyl iron complexes.
|
|
670
|
|
|
‡a
Author's The novel iron chelator, 2-pyridylcarboxaldehyde 2-thiophenecarboxyl hydrazone, reduces catecholamine-mediated myocardial toxicity
|
|
670
|
|
|
‡a
Author's The novel thiosemicarbazone, di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone (DpC), inhibits neuroblastoma growth in vitro and in vivo via multiple mechanisms.
|
|
670
|
|
|
‡a
Author's The old and new biochemistry of polyamines
|
|
670
|
|
|
‡a
Author's The potent and novel thiosemicarbazone chelators di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone and 2-benzoylpyridine-4,4-dimethyl-3-thiosemicarbazone affect crucial thiol systems required for ribonucleotide reductase activity.
|
|
670
|
|
|
‡a
Author's The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents, IV: The mechanisms involved in inhibiting cell-cycle progression
|
|
670
|
|
|
‡a
Author's The redox-active, anti-cancer drug Dp44mT inhibits T-cell activation and CD25 through a copper-dependent mechanism.
|
|
670
|
|
|
‡a
Author's The release of iron and transferrin from the human melanoma cell
|
|
670
|
|
|
‡a
Author's The renaissance of polypharmacology in the development of anti-cancer therapeutics: Inhibition of the "Triad of Death" in cancer by Di-2-pyridylketone thiosemicarbazones.
|
|
670
|
|
|
‡a
Author's The role of hypoxia and nitrogen monoxide in the regulation of cellular iron metabolism.
|
|
670
|
|
|
‡a
Author's The role of NDRG1 in the pathology and potential treatment of human cancers
|
|
670
|
|
|
‡a
Author's The Role of the Antioxidant Response in Mitochondrial Dysfunction in Degenerative Diseases: Cross-Talk between Antioxidant Defense, Autophagy, and Apoptosis
|
|
670
|
|
|
‡a
Author's The TGF-beta, PI3K/Akt and PTEN pathways: established and proposed biochemical integration in prostate cancer
|
|
670
|
|
|
‡a
Author's The transferrin homologue, melanotransferrin (p97), is rapidly catabolized by the liver of the rat and does not effectively donate iron to the brain
|
|
670
|
|
|
‡a
Author's The translational regulator eIF3a: the tricky eIF3 subunit!
|
|
670
|
|
|
‡a
Author's The uptake of inorganic iron complexes by human melanoma cells
|
|
670
|
|
|
‡a
Author's The uptake of iron and transferrin by the human malignant melanoma cell
|
|
670
|
|
|
‡a
Author's The use of iron chelators in biocidal compositions: evaluation of patent, WO2014059417A1
|
|
670
|
|
|
‡a
Author's Thiosemicarbazones from the old to new: iron chelators that are more than just ribonucleotide reductase inhibitors.
|
|
670
|
|
|
‡a
Author's Thiosemicarbazones: the new wave in cancer treatment
|
|
670
|
|
|
‡a
Author's Transcriptional regulation of the cyclin-dependent kinase inhibitor, p21CIP1/WAF1, by the chelator, Dp44mT.
|
|
670
|
|
|
‡a
Author's Tumor stressors induce two mechanisms of intracellular p-glycoprotein-mediated resistance that are overcome by lysosomal-targeted thiosemicarbazones.
|
|
670
|
|
|
‡a
Author's Tuning the antiproliferative activity of biologically active iron chelators: characterization of the coordination chemistry and biological efficacy of 2-acetylpyridine and 2-benzoylpyridine hydrazone ligands
|
|
670
|
|
|
‡a
Author's Turning the gun on cancer: Utilizing lysosomal P-glycoprotein as a new strategy to overcome multi-drug resistance.
|
|
670
|
|
|
‡a
Author's Two saturable mechanisms of iron uptake from transferrin in human melanoma cells: the effect of transferrin concentration, chelators, and metabolic probes on transferrin and iron uptake
|
|
670
|
|
|
‡a
Author's Unexpected anthracycline-mediated alterations in iron-regulatory protein-RNA-binding activity: the iron and copper complexes of anthracyclines decrease RNA-binding activity
|
|
670
|
|
|
‡a
Author's Unprecedented oxidation of a biologically active aroylhydrazone chelator catalysed by iron
|
|
670
|
|
|
‡a
Author's Unprecedented oxidation of a biologically active aroylhydrazone chelator catalysed by iron(III): serendipitous identification of diacylhydrazine ligands with high iron chelation efficacy
|
|
670
|
|
|
‡a
Author's Unraveling the mysteries of serum albumin-more than just a serum protein.
|
|
670
|
|
|
‡a
Author's Zinc(II)-Thiosemicarbazone Complexes Are Localized to the Lysosomal Compartment Where They Transmetallate with Copper Ions to Induce Cytotoxicity.
|
|
909
|
|
|
‡a
(scopus) 57198449378
‡9
1
|
|
909
|
|
|
‡a
(scopus) 7403445073
‡9
1
|
|
909
|
|
|
‡a
(orcid) 0000000309606415
‡9
1
|
|
912
|
|
|
‡a
tabibisabbu
‡A
Tabibi Sabbu
‡9
1
|
|
912
|
|
|
‡a
guidelinesfortheuseandinterpretationofassaysformonitoringautophagy3edition
‡A
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)
‡9
1
|
|
912
|
|
|
‡a
scientificarticle
‡A
en scientific article
‡9
1
|
|
919
|
|
|
‡a
synthesisandbiologicalevaluationof2benzoylpyridinethiosemicarbazonesinadimericsystemstructureactivityrelationshipstudiesontheirantiproliferativeandironchelationefficacy
‡A
Synthesis and biological evaluation of 2-benzoylpyridine thiosemicarbazones in a dimeric system: structure-activity relationship studies on their anti-proliferative and iron chelation efficacy.
‡9
1
|
|
919
|
|
|
‡a
structureactivityrelationshipsofnovelironchelatorsforthetreatmentofironoverloaddiseasethemethylpyrazinylketoneisonicotinoylhydrazoneseries
‡A
Structure-activity relationships of novel iron chelators for the treatment of iron overload disease: the methyl pyrazinylketone isonicotinoyl hydrazone series.
‡9
1
|
|
919
|
|
|
‡a
synthesisandbiologicalevaluationofsubstituted2benzoylpyridinethiosemicarbazonesnovelstructureactivityrelationshipsunderpinningtheirantiproliferativeandchelationefficacy
‡A
Synthesis and biological evaluation of substituted 2-benzoylpyridine thiosemicarbazones: novel structure-activity relationships underpinning their anti-proliferative and chelation efficacy
‡9
1
|
|
919
|
|
|
‡a
structureactivityrelationshipsof5012pyridylketone2benzoylpyridineand2acetylpyridinethiosemicarbazonesforovercomingpgpmediateddrugresistance
‡A
Structure-Activity Relationships of Di-2-pyridylketone, 2-Benzoylpyridine, and 2-Acetylpyridine Thiosemicarbazones for Overcoming Pgp-Mediated Drug Resistance.
‡9
1
|
|
919
|
|
|
‡a
synthesisandcharacterizationofquinolinebasedthiosemicarbazonesandcorrelationofcellularironbindingefficacytoantitumorefficacy
‡A
Synthesis and characterization of quinoline-based thiosemicarbazones and correlation of cellular iron-binding efficacy to anti-tumor efficacy
‡9
1
|
|
919
|
|
|
‡a
simultaneousdeterminationofthenovelthiosemicarbazoneanticanceragentbp4etanditsmainphase1metabolitesinplasmaapplicationtoapilotpharmacokineticstudyinrats
‡A
Simultaneous determination of the novel thiosemicarbazone anti-cancer agent, Bp4eT, and its main phase I metabolites in plasma: application to a pilot pharmacokinetic study in rats
‡9
1
|
|
919
|
|
|
‡a
synthesischaracterizationandinvitroanticanceractivityofcopperandzincbisthiosemicarbazonecomplexes
‡A
Synthesis, Characterization, and in Vitro Anticancer Activity of Copper and Zinc Bis(Thiosemicarbazone) Complexes
‡9
1
|
|
919
|
|
|
‡a
siderocalinlcn2ngal24p3doesnotdriveapoptosisthroughgentisicacidmediatedironwithdrawalinhematopoieticcelllines
‡A
Siderocalin/Lcn2/NGAL/24p3 does not drive apoptosis through gentisic acid mediated iron withdrawal in hematopoietic cell lines
‡9
1
|
|
919
|
|
|
‡a
syntheticandnaturalproductsasironchelators
‡A
Synthetic and natural products as iron chelators
‡9
1
|
|
919
|
|
|
‡a
roleofglutaredoxin1andglutathioneinregulatingtheactivityofthecoppertransportingptypeatpasesatp7aandatp7b
‡A
Role of glutaredoxin1 and glutathione in regulating the activity of the copper-transporting P-type ATPases, ATP7A and ATP7B.
‡9
1
|
|
919
|
|
|
‡a
targetingautophagyinantitumoragentdesignfurtheringthelysosomallovestrategy
‡A
Targeting autophagy in antitumor agent design: furthering the 'lysosomal love' strategy.
‡9
1
|
|
919
|
|
|
‡a
roleofceruloplasminandascorbateincellularironrelease
‡A
Role of ceruloplasmin and ascorbate in cellular iron release
‡9
1
|
|
919
|
|
|
‡a
roadstomelanomakeypathwaysandemergingplayersinmelanomaprogressionandoncogenicsignaling
‡A
Roads to melanoma: Key pathways and emerging players in melanoma progression and oncogenic signaling
‡9
1
|
|
919
|
|
|
‡a
resistancetotheantineoplasticagentgalliumnitrateresultsinmarkedalterationsinintracellularironandgalliumtraffickingidentificationofnovelintermediates
‡A
Resistance to the antineoplastic agent gallium nitrate results in marked alterations in intracellular iron and gallium trafficking: identification of novel intermediates
‡9
1
|
|
919
|
|
|
‡a
regulationandcontrolofnitricoxidenoinmacrophagesprotectingtheprofessionalkillercellfromitsowncytotoxicarsenalviamrp1andgstp1
‡A
Regulation and control of nitric oxide (NO) in macrophages: Protecting the "professional killer cell" from its own cytotoxic arsenal via MRP1 and GSTP1.
‡9
1
|
|
919
|
|
|
‡a
regulationandcontrolofnitricoxide
‡A
Regulation and control of nitric oxide
‡9
1
|
|
919
|
|
|
‡a
redoxcyclingmetalspedalingtheirrolesinmetabolismandtheiruseinthedevelopmentofnoveltherapeutics
‡A
Redox cycling metals: Pedaling their roles in metabolism and their use in the development of novel therapeutics
‡9
1
|
|
919
|
|
|
‡a
pyridoxalisonicotinoylhydrazoneandanaloguesstudyoftheirstabilityinacidicneutralandbasicaqueoussolutionsbyultravioletvisiblespectrophotometry
‡A
Pyridoxal isonicotinoyl hydrazone and analogues. Study of their stability in acidic, neutral and basic aqueous solutions by ultraviolet-visible spectrophotometry
‡9
1
|
|
919
|
|
|
‡a
protontransferandferredoxin1thesecretsofredoxdrivenprotontransferbetweensolventandaburiedironsulphurcluster
‡A
Proton transfer and ferredoxin I: the secrets of redox-driven proton transfer between solvent and a buried iron-sulphur cluster.
‡9
1
|
|
919
|
|
|
‡a
targetingcancerbybindingirondissectingcellularsignalingpathways
‡A
Targeting cancer by binding iron: Dissecting cellular signaling pathways
‡9
1
|
|
919
|
|
|
‡a
proteomicanalysisofheartsfromfrataxinknockoutmicemarkedrearrangementofenergymetabolismaresponsetocellularstressandalteredexpressionofproteinsinvolvedincellstructuremotilityandmetabolism
‡A
Proteomic analysis of hearts from frataxin knockout mice: marked rearrangement of energy metabolism, a response to cellular stress and altered expression of proteins involved in cell structure, motility and metabolism
‡9
1
|
|
919
|
|
|
‡a
targetingoncogenicnfκbsignalingwithredoxactiveagentsforcancertreatment
‡A
Targeting Oncogenic NF-κB Signaling with Redox-Active Agents for Cancer Treatment
‡9
1
|
|
919
|
|
|
‡a
proteolyticcleavageandtruncationofndrg1inhumanprostatecancercellsbutnotnormalprostateepithelialcells
‡A
Proteolytic cleavage and truncation of NDRG1 in human prostate cancer cells, but not normal prostate epithelial cells.
‡9
1
|
|
919
|
|
|
‡a
targetingthemetastasissuppressornmycdownstreamregulatedgene1withnovel5012pyridylketonethiosemicarbazonessuppressionoftumorcellmigrationandcellcollagenadhesionbyinhibitingfocaladhesionkinasepaxillinsignaling
‡A
Targeting the Metastasis Suppressor, N-Myc Downstream Regulated Gene-1, with Novel Di-2-Pyridylketone Thiosemicarbazones: Suppression of Tumor Cell Migration and Cell-Collagen Adhesion by Inhibiting Focal Adhesion Kinase/Paxillin Signaling.
‡9
1
|
|
919
|
|
|
‡a
protectionagainsthydrogenperoxidemediatedcytotoxicityinfriedreichsataxiafibroblastsusingnovelironchelatorsofthe2pyridylcarboxaldehydeisonicotinoylhydrazoneclass
‡A
Protection against hydrogen peroxide-mediated cytotoxicity in Friedreich's ataxia fibroblasts using novel iron chelators of the 2-pyridylcarboxaldehyde isonicotinoyl hydrazone class.
‡9
1
|
|
919
|
|
|
‡a
targetingthemetastasissuppressorndrg1usingnovelironchelatorsregulationofstressfibermediatedtumorcellmigrationviamodulationoftherock1pmlc2signalingpathway
‡A
Targeting the metastasis suppressor, NDRG1, using novel iron chelators: regulation of stress fiber-mediated tumor cell migration via modulation of the ROCK1/pMLC2 signaling pathway
‡9
1
|
|
919
|
|
|
‡a
potentialofironchelatorsaseffectiveantiproliferativeagents
‡A
Potential of iron chelators as effective antiproliferative agents
‡9
1
|
|
919
|
|
|
‡a
activeroleofvitamin100inmammalianironmetabolismmuchmorethanjustenhancedironabsorption
‡A
The active role of vitamin C in mammalian iron metabolism: much more than just enhanced iron absorption!
‡9
1
|
|
919
|
|
|
‡a
potentironchelatorsincreasethemrnalevelsoftheuniversalcyclindependentkinaseinhibitorp21cip1waf1butparadoxicallyinhibititstranslationapotentialmechanismofcellcycledysregulation
‡A
Potent iron chelators increase the mRNA levels of the universal cyclin-dependent kinase inhibitor p21(CIP1/WAF1), but paradoxically inhibit its translation: a potential mechanism of cell cycle dysregulation
‡9
1
|
|
919
|
|
|
‡a
anticanceragent5012pyridylketone44dimethyl3thiosemicarbazonedp44mtovercomesprosurvivalautophagyby2mechanismspersistentinductionofautophagosomesynthesisandimpairmentoflysosomalintegrity
‡A
The anticancer agent di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT) overcomes prosurvival autophagy by two mechanisms: persistent induction of autophagosome synthesis and impairment of lysosomal integrity.
‡9
1
|
|
919
|
|
|
‡a
potentantitumoractivityofnovelironchelatorsderivedfrom5012pyridylketoneisonicotinoylhydrazoneinvolvesfentonderivedfreeradicalgeneration
‡A
Potent antitumor activity of novel iron chelators derived from di-2-pyridylketone isonicotinoyl hydrazone involves fenton-derived free radical generation
‡9
1
|
|
919
|
|
|
‡a
anticanceragent5012pyridylketone44dimethyl3thiosemicarbazonedp44mtupregulatestheampkdependentenergyhomeostasispathwayincancercells
‡A
The Anticancer Agent, Di-2-Pyridylketone 4,4-Dimethyl-3-Thiosemicarbazone (Dp44mT), Up-Regulates the AMPK-Dependent Energy Homeostasis Pathway in Cancer Cells
‡9
1
|
|
919
|
|
|
‡a
potentantimycobacterialactivityofthepyridoxalisonicotinoylhydrazoneanalog2pyridylcarboxaldehydeisonicotinoylhydrazonealipophilictransportvehicleforisonicotinicacidhydrazide
‡A
Potent antimycobacterial activity of the pyridoxal isonicotinoyl hydrazone analog 2-pyridylcarboxaldehyde isonicotinoyl hydrazone: a lipophilic transport vehicle for isonicotinic acid hydrazide.
‡9
1
|
|
919
|
|
|
‡a
biogenesisofclusterstheroleoftheunorthodoxabcatpasesufcandthewiderimplicationsforunderstandingironmetabolism
‡A
The biogenesis of [Fe-S] clusters: the role of the unorthodox ABC ATPase, SufC, and the wider implications for understanding iron metabolism
‡9
1
|
|
919
|
|
|
‡a
pharmacologicaltargetingoftheintegratedproteinkinasebphosphataseandtensinhomologdeletedonchromosome10andtransforminggrowthfactorbetapathwaysinprostatecancer
‡A
Pharmacological targeting of the integrated protein kinase B, phosphatase and tensin homolog deleted on chromosome 10, and transforming growth factor-beta pathways in prostate cancer.
‡9
1
|
|
919
|
|
|
‡a
cardioprotectiveeffectoftheironchelatordexrazoxane
‡A
The cardioprotective effect of the iron chelator dexrazoxane
‡9
1
|
|
919
|
|
|
‡a
pharmacologicaltargetingofmitochondriaincancerstemcellsanancientorganelleatthecrossroadofnovelanticancertherapies
‡A
Pharmacological targeting of mitochondria in cancer stem cells: An ancient organelle at the crossroad of novel anti-cancer therapies
‡9
1
|
|
919
|
|
|
‡a
cardioprotectiveeffectoftheironchelatordexrazoxaneicrf187onanthracyclinemediatedcardiotoxicity
‡A
The cardioprotective effect of the iron chelator dexrazoxane (ICRF-187) on anthracycline-mediated cardiotoxicity.
‡9
1
|
|
919
|
|
|
‡a
pgrmc1regulationbyphosphorylationpotentialnewinsightsincontrollingbiologicalactivity
‡A
PGRMC1 regulation by phosphorylation: potential new insights in controlling biological activity!
‡9
1
|
|
919
|
|
|
‡a
pcthanovelorallyactivechelatorofthearoylhydrazoneclassthatinducesironexcretionfrommice
‡A
PCTH: a novel orally active chelator of the aroylhydrazone class that induces iron excretion from mice.
‡9
1
|
|
919
|
|
|
‡a
pglycoproteinmediatesdrugresistanceviaanovelmechanisminvolvinglysosomalsequestration
‡A
P-glycoprotein mediates drug resistance via a novel mechanism involving lysosomal sequestration.
‡9
1
|
|
919
|
|
|
‡a
novelthiosemicarbazonesregulatethesignaltransducerandactivatoroftranscription3stat3pathwayinhibitionofconstitutiveandinterleukin6inducedactivationbyirondepletion
‡A
Novel thiosemicarbazones regulate the signal transducer and activator of transcription 3 (STAT3) pathway: inhibition of constitutive and interleukin 6-induced activation by iron depletion
‡9
1
|
|
919
|
|
|
‡a
novelthiosemicarbazonesoftheaptanddptseriesandtheircoppercomplexesidentificationofpronouncedredoxactivityandcharacterizationoftheirantitumoractivity
‡A
Novel thiosemicarbazones of the ApT and DpT series and their copper complexes: identification of pronounced redox activity and characterization of their antitumor activity.
‡9
1
|
|
919
|
|
|
‡a
novelthiosemicarbazonesinhibitlysinerichcarcinoembryonicantigenrelatedcelladhesionmolecule1ceacam1coisolatedlyricandthelyricinducedepithelialmesenchymaltransitionviaupregulationofnmycdownstreamregulatedgene1ndrg1
‡A
Novel Thiosemicarbazones Inhibit Lysine-Rich Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 (CEACAM1) Coisolated (LYRIC) and the LYRIC-Induced Epithelial-Mesenchymal Transition via Upregulation of N-Myc Downstream-Regulated Gene 1 (NDRG1)
‡9
1
|
|
919
|
|
|
‡a
novelthiosemicarbazoneironchelatorsinduceupregulationandphosphorylationofthemetastasissuppressornmycdownstreamregulatedgene1anewstrategyforthetreatmentofpancreaticcancer
‡A
Novel thiosemicarbazone iron chelators induce up-regulation and phosphorylation of the metastasis suppressor N-myc down-stream regulated gene 1: a new strategy for the treatment of pancreatic cancer
‡9
1
|
|
919
|
|
|
‡a
novel2generation5012pyridylketonethiosemicarbazonesshowsynergismwithstandardchemotherapeuticsanddemonstratepotentactivityagainstlungcancerxenograftsafteroralandintravenousadministrationinvivo
‡A
Novel second-generation di-2-pyridylketone thiosemicarbazones show synergism with standard chemotherapeutics and demonstrate potent activity against lung cancer xenografts after oral and intravenous administration in vivo.
‡9
1
|
|
919
|
|
|
‡a
novelmechanismofcytotoxicityfortheselectiveselenosemicarbazone2acetylpyridine44dimethyl3selenosemicarbazoneap44mselysosomalmembranepermeabilization
‡A
Novel Mechanism of Cytotoxicity for the Selective Selenosemicarbazone, 2-Acetylpyridine 4,4-Dimethyl-3-selenosemicarbazone (Ap44mSe): Lysosomal Membrane Permeabilization
‡9
1
|
|
919
|
|
|
‡a
novelhybridironchelatorsderivedfromaroylhydrazonesandthiosemicarbazonesdemonstrateselectiveantiproliferativeactivityagainsttumorcells
‡A
Novel "hybrid" iron chelators derived from aroylhydrazones and thiosemicarbazones demonstrate selective antiproliferative activity against tumor cells
‡9
1
|
|
919
|
|
|
‡a
noveldiaroylhydrazineligandsasironchelatorscoordinationchemistryandbiologicalactivity
‡A
Novel diaroylhydrazine ligands as iron chelators: coordination chemistry and biological activity.
‡9
1
|
|
919
|
|
|
‡a
novel5012pyridylderivedironchelatorswithmarkedandselectiveantitumoractivityinvitroandinvivoassessment
‡A
Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment.
‡9
1
|
|
919
|
|
|
‡a
novelchelatorsforcentralnervoussystemdisordersthatinvolvealterationsinthemetabolismofironandothermetalions
‡A
Novel chelators for central nervous system disorders that involve alterations in the metabolism of iron and other metal ions.
‡9
1
|
|
919
|
|
|
‡a
novelchelatorsforcancertreatmentwherearewenow
‡A
Novel chelators for cancer treatment: where are we now?
‡9
1
|
|
919
|
|
|
‡a
novelchelatorsbasedonadamantanederivedsemicarbazonesandhydrazonesthattargetmultiplehallmarksofalzheimersdisease
‡A
Novel chelators based on adamantane-derived semicarbazones and hydrazones that target multiple hallmarks of Alzheimer's disease
‡9
1
|
|
919
|
|
|
‡a
novelaroylhydrazoneandthiosemicarbazoneironchelatorswithantimalarialactivityagainstchloroquineresistantandsensitiveparasites
‡A
Novel aroylhydrazone and thiosemicarbazone iron chelators with anti-malarial activity against chloroquine-resistant and -sensitive parasites
‡9
1
|
|
919
|
|
|
‡a
novelandpotentantitumorandantimetastatic5012pyridylketonethiosemicarbazonesdemonstratemarkeddifferencesinpharmacologybetweenthe1and2generationleadagents
‡A
Novel and potent anti-tumor and anti-metastatic di-2-pyridylketone thiosemicarbazones demonstrate marked differences in pharmacology between the first and second generation lead agents.
‡9
1
|
|
919
|
|
|
‡a
nonthermalplasmainducesastressresponseinmesotheliomacellsresultinginincreasedendocytosislysosomebiogenesisandautophagy
‡A
Non-thermal plasma induces a stress response in mesothelioma cells resulting in increased endocytosis, lysosome biogenesis and autophagy.
‡9
1
|
|
919
|
|
|
‡a
nitrogenmonoxidenomediatedironreleasefromcellsislinkedtonoinducedglutathioneeffluxviamultidrugresistanceassociatedprotein1
‡A
Nitrogen monoxide (NO)-mediated iron release from cells is linked to NO-induced glutathione efflux via multidrug resistance-associated protein 1.
‡9
1
|
|
919
|
|
|
‡a
nitrogenmonoxidenoandglucoseunexpectedlinksbetweenenergymetabolismandnomediatedironmobilizationfromcells
‡A
Nitrogen monoxide (no) and glucose: unexpected links between energy metabolism and no-mediated iron mobilization from cells
‡9
1
|
|
919
|
|
|
‡a
nitrogenmonoxidedecreasesironuptakefromtransferrinbutdoesnotmobiliseironfromprelabelledneoplasticcells
‡A
Nitrogen monoxide decreases iron uptake from transferrin but does not mobilise iron from prelabelled neoplastic cells
‡9
1
|
|
919
|
|
|
‡a
nitrogenmonoxideactivatesironregulatoryprotein1rnabindingactivityby2possiblemechanismseffectontheclusterandironmobilizationfromcells
‡A
Nitrogen monoxide activates iron regulatory protein 1 RNA-binding activity by two possible mechanisms: effect on the [4Fe-4S] cluster and iron mobilization from cells
‡9
1
|
|
919
|
|
|
‡a
nitrogenmonoxide
‡A
Nitrogen monoxide
‡9
1
|
|
919
|
|
|
‡a
ndrg1asamoleculartargettoinhibittheepithelialmesenchymaltransitionthecasefordevelopinginhibitorsofmetastasis
‡A
NDRG1 as a molecular target to inhibit the epithelial-mesenchymal transition: the case for developing inhibitors of metastasis
‡9
1
|
|
919
|
|
|
‡a
nmycdownstreamregulated1ndrg1isregulatedbyeukaryoticinitiationfactor3aeif3aduringcellularstresscausedbyirondepletion
‡A
N-myc downstream regulated 1 (NDRG1) is regulated by eukaryotic initiation factor 3a (eIF3a) during cellular stress caused by iron depletion.
‡9
1
|
|
919
|
|
|
‡a
nmycdownstreamregulated1
‡A
N-myc downstream regulated 1
‡9
1
|
|
919
|
|
|
‡a
mysteriesofthetransferrintransferrinreceptor1interactionuncovered
‡A
Mysteries of the transferrin-transferrin receptor 1 interaction uncovered
‡9
1
|
|
919
|
|
|
‡a
multipleeffectsofironchelatorsonmoleculescontrollingcellcycleprogression
‡A
Multiple effects of iron chelators on molecules controlling cell cycle progression
‡9
1
|
|
919
|
|
|
‡a
controversialroleofdeferiproneinthetreatmentofthalassemia
‡A
The controversial role of deferiprone in the treatment of thalassemia.
‡9
1
|
|
919
|
|
|
‡a
doubleedgednatureofusinggeneticdatabasesmelanotransferringenesandtranscripts
‡A
The double-edged nature of using genetic databases: melanotransferrin genes and transcripts
‡9
1
|
|
919
|
|
|
‡a
effectofdesferrioxamineandferricammoniumcitrateontheuptakeofironbythemembraneironbindingcomponentofhumanmelanomacells
‡A
The effect of desferrioxamine and ferric ammonium citrate on the uptake of iron by the membrane iron-binding component of human melanoma cells
‡9
1
|
|
919
|
|
|
‡a
effectofintracellularironconcentrationandnitrogenmonoxideonnramp2expressionandnontransferrinboundironuptake
‡A
The effect of intracellular iron concentration and nitrogen monoxide on Nramp2 expression and non-transferrin-bound iron uptake
‡9
1
|
|
919
|
|
|
‡a
effectofpotentironchelatorsontheregulationofp53examinationoftheexpressionlocalizationanddnabindingactivityofp53andthetransactivationofwaf1
‡A
The effect of potent iron chelators on the regulation of p53: examination of the expression, localization and DNA-binding activity of p53 and the transactivation of WAF1.
‡9
1
|
|
919
|
|
|
‡a
emergingroleofprogesteronereceptormembranecomponent1pgrmc1incancerbiology
‡A
The emerging role of progesterone receptor membrane component 1 (PGRMC1) in cancer biology.
‡9
1
|
|
919
|
|
|
‡a
evolutionofironchelatorsforthetreatmentofironoverloaddiseaseandcancer
‡A
The evolution of iron chelators for the treatment of iron overload disease and cancer.
‡9
1
|
|
919
|
|
|
‡a
functionofmelanotransferrinaroleinmelanomacellproliferationandtumorigenesis
‡A
The function of melanotransferrin: a role in melanoma cell proliferation and tumorigenesis.
‡9
1
|
|
919
|
|
|
‡a
insandoutsofmitochondrialironloadingthemetabolicdefectinfriedreichsataxia
‡A
The ins and outs of mitochondrial iron-loading: the metabolic defect in Friedreich's ataxia.
‡9
1
|
|
919
|
|
|
‡a
ironchaperonepolyrcbindingprotein2formsametabolonwiththehemeoxygenase1cytochromep450reductasecomplexforhemecatabolismandirontransfer
‡A
The iron chaperone poly(rC)-binding protein 2 forms a metabolon with the heme oxygenase 1/cytochrome P450 reductase complex for heme catabolism and iron transfer
‡9
1
|
|
919
|
|
|
‡a
molecularpharmacologyofabcg2anditsroleinchemoresistance
‡A
Molecular pharmacology of ABCG2 and its role in chemoresistance
‡9
1
|
|
919
|
|
|
‡a
molecularfunctionsoftheironregulatedmetastasissuppressorndrg1anditspotentialasamoleculartargetforcancertherapy
‡A
Molecular functions of the iron-regulated metastasis suppressor, NDRG1, and its potential as a molecular target for cancer therapy.
‡9
1
|
|
919
|
|
|
‡a
molecularandfunctionalalterationsinamousecardiacmodeloffriedreichataxiaactivationoftheintegratedstressresponseeif2αphosphorylationandtheinductionofdownstreamtargets
‡A
Molecular and functional alterations in a mouse cardiac model of Friedreich ataxia: activation of the integrated stress response, eIF2α phosphorylation, and the induction of downstream targets.
‡9
1
|
|
919
|
|
|
‡a
molecularalterationsinamousecardiacmodeloffriedreichataxiaanimpairednrf2responsemediatedviaupregulationofkeap1andactivationofthegsk3βaxis
‡A
Molecular Alterations in a Mouse Cardiac Model of Friedreich Ataxia: An Impaired Nrf2 Response Mediated via Upregulation of Keap1 and Activation of the Gsk3β Axis.
‡9
1
|
|
919
|
|
|
‡a
mitochondrialmayhemthemitochondrionasamodulatorofironmetabolismanditsroleindisease
‡A
Mitochondrial mayhem: the mitochondrion as a modulator of iron metabolism and its role in disease
‡9
1
|
|
919
|
|
|
‡a
mitochondrialironmetabolismandsideroblasticanemia
‡A
Mitochondrial iron metabolism and sideroblastic anemia
‡9
1
|
|
919
|
|
|
‡a
mitochondrialdysfunctionintheneurodegenerativeandcardiodegenerativediseasefriedreichsataxia
‡A
Mitochondrial dysfunction in the neuro-degenerative and cardio-degenerative disease, Friedreich's ataxia.
‡9
1
|
|
919
|
|
|
‡a
methemoglobinformationbytriapine5012pyridylketone44dimethyl3thiosemicarbazonedp44mtandotheranticancerthiosemicarbazonesidentificationofnovelthiosemicarbazonesandtherapeuticsthatpreventthiseffect
‡A
Methemoglobin formation by triapine, di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone (Dp44mT), and other anticancer thiosemicarbazones: identification of novel thiosemicarbazones and therapeutics that prevent this effect
‡9
1
|
|
919
|
|
|
‡a
metastasissuppressorndrg1mediatesitsactivitythroughsignalingpathwaysandmolecularmotors
‡A
Metastasis suppressor, NDRG1, mediates its activity through signaling pathways and molecular motors.
‡9
1
|
|
919
|
|
|
‡a
metalsandmetastasisexploitingtheroleofmetalsincancermetastasistodevelopnovelantimetastaticagents
‡A
Metals and metastasis: Exploiting the role of metals in cancer metastasis to develop novel anti-metastatic agents.
‡9
1
|
|
919
|
|
|
‡a
metalchelation
‡A
Metal chelation
‡9
1
|
|
919
|
|
|
‡a
membranetransportandintracellularsequestrationofnovelthiosemicarbazonechelatorsforthetreatmentofcancer
‡A
Membrane transport and intracellular sequestration of novel thiosemicarbazone chelators for the treatment of cancer.
‡9
1
|
|
919
|
|
|
‡a
ironchelatordeferasiroxasanovelstrategyforcancertreatmentoralactivityagainsthumanlungtumorxenograftsandmolecularmechanismofaction
‡A
The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action
‡9
1
|
|
919
|
|
|
‡a
ironchelatorsdp44mtanddfoinhibittgfβinducedepithelialmesenchymaltransitionviaupregulationofnmycdownstreamregulatedgene1
‡A
The iron chelators Dp44mT and DFO inhibit TGF-β-induced epithelial-mesenchymal transition via up-regulation of N-Myc downstream-regulated gene 1
‡9
1
|
|
919
|
|
|
‡a
ironchelatorsdp44mtanddfoinhibittgfβinducedepithelialmesenchymaltransitionviaupregulationofnmycdownstreamregulatedgene1ndrg1
‡A
The iron chelators Dp44mT and DFO inhibit TGF-β-induced epithelial-mesenchymal transition via up-regulation of N-Myc downstream-regulated gene 1 (NDRG1).
‡9
1
|
|
919
|
|
|
‡a
ironcomplexofdp44mtisredoxactiveandinduceshydroxylradicalformationaneprstudy
‡A
The iron complex of Dp44mT is redox-active and induces hydroxyl radical formation: an EPR study.
‡9
1
|
|
919
|
|
|
‡a
ironregulatedmetastasissuppressorndrg1identificationofnovelmoleculartargets
‡A
The iron-regulated metastasis suppressor, Ndrg-1: identification of novel molecular targets
‡9
1
|
|
919
|
|
|
‡a
ironregulatedmetastasissuppressorndrg1targetsnedd4lptenandsmad4andinhibitsthepi3kandrassignalingpathways
‡A
The iron-regulated metastasis suppressor NDRG1 targets NEDD4L, PTEN, and SMAD4 and inhibits the PI3K and Ras signaling pathways
‡9
1
|
|
919
|
|
|
‡a
lureofalyrthelogisticsofironsulfurclusterdelivery
‡A
The lure of a LYR: The logistics of iron sulfur cluster delivery
‡9
1
|
|
919
|
|
|
‡a
mechanismofnitrogenmonoxide
‡A
The mechanism of nitrogen monoxide
‡9
1
|
|
919
|
|
|
‡a
mechanismofnitrogenmonoxidenomediatedironmobilizationfromcellsnointerceptsironbeforeincorporationintoferritinandindirectlymobilizesironfromferritininaglutathionedependentmanner
‡A
The mechanism of nitrogen monoxide (NO)-mediated iron mobilization from cells. NO intercepts iron before incorporation into ferritin and indirectly mobilizes iron from ferritin in a glutathione-dependent manner
‡9
1
|
|
919
|
|
|
‡a
mechanisticroleofchemicallydiversemetalionsintheinductionofautophagy
‡A
The mechanistic role of chemically diverse metal ions in the induction of autophagy
‡9
1
|
|
919
|
|
|
‡a
melanotransferrinsearchforafunction
‡A
Melanotransferrin: search for a function.
‡9
1
|
|
919
|
|
|
‡a
mechanismoftheinductionofendoplasmicreticulumstressbytheanticanceragent5012pyridylketone44dimethyl3thiosemicarbazonedp44mtactivationofperkeif2αire1αatf6andcalmodulinkinase
‡A
Mechanism of the induction of endoplasmic reticulum stress by the anti-cancer agent, di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT): Activation of PERK/eIF2α, IRE1α, ATF6 and calmodulin kinase
‡9
1
|
|
919
|
|
|
‡a
makingacaseforalbuminahighlypromisingdrugdeliverysystem
‡A
Making a case for albumin – a highly promising drug-delivery system.
‡9
1
|
|
919
|
|
|
‡a
lysosomalmembranestabilityplaysamajorroleinthecytotoxicactivityoftheantiproliferativeagent5012pyridylketone44dimethyl3thiosemicarbazonedp44mt
‡A
Lysosomal membrane stability plays a major role in the cytotoxic activity of the anti-proliferative agent, di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT).
‡9
1
|
|
919
|
|
|
‡a
lipidbaseddrugdeliverysystemsincancertherapywhatisavailableandwhatisyettocome
‡A
Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come.
‡9
1
|
|
919
|
|
|
‡a
medicinalchemistryofnovelironchelatorsforthetreatmentofcancer
‡A
The medicinal chemistry of novel iron chelators for the treatment of cancer.
‡9
1
|
|
919
|
|
|
‡a
melanomatumorantigenmelanotransferrinp97a25yearhallmarkfromironmetabolismtotumorigenesis
‡A
The melanoma tumor antigen, melanotransferrin (p97): a 25-year hallmark--from iron metabolism to tumorigenesis.
‡9
1
|
|
919
|
|
|
‡a
metastasissuppressornmycdownstreamregulatedgene1ndrg1downregulatestheerbbfamilyofreceptorstoinhibitdownstreamoncogenicsignalingpathways
‡A
The Metastasis Suppressor, N-MYC Downstream-regulated Gene-1 (NDRG1), Down-regulates the ErbB Family of Receptors to Inhibit Downstream Oncogenic Signaling Pathways
‡9
1
|
|
919
|
|
|
‡a
metastasissuppressornmycdownstreamregulatedgene1ndrg1inhibitsstressinducedautophagyincancercells
‡A
The metastasis suppressor, N-myc downstream-regulated gene 1 (NDRG1), inhibits stress-induced autophagy in cancer cells.
‡9
1
|
|
919
|
|
|
‡a
metastasissuppressornmycdownstreamregulatedgene1ndrg1upregulatesp21viap53independentmechanisms
‡A
The metastasis suppressor, N-myc downstream regulated gene 1 (NDRG1), upregulates p21 via p53-independent mechanisms.
‡9
1
|
|
919
|
|
|
‡a
metastasissuppressorndrg1anewallyinthefightagainstcancer
‡A
The metastasis suppressor, Ndrg-1: a new ally in the fight against cancer
‡9
1
|
|
919
|
|
|
‡a
lcmsmsidentificationoftheprincipalinvitroandinvivophase1metabolitesofthenovelthiosemicarbazoneanticancerdrugbp4et
‡A
LC-MS/MS identification of the principal in vitro and in vivo phase I metabolites of the novel thiosemicarbazone anti-cancer drug, Bp4eT.
‡9
1
|
|
919
|
|
|
‡a
layingdownasolidironfoundationprofessorericabaker
‡A
Laying Down a Solid "Iron Foundation": Professor Erica Baker
‡9
1
|
|
919
|
|
|
‡a
kineticomechanisticstudiesonmethemoglobingenerationbybiologicallyactivethiosemicarbazoneiron3complexes
‡A
Kinetico-mechanistic studies on methemoglobin generation by biologically active thiosemicarbazone iron(III) complexes
‡9
1
|
|
919
|
|
|
‡a
kineticstudiesontheoxidationofoxyhemoglobinbybiologicallyactiveironthiosemicarbazonecomplexesrelevancetoironchelatorinducedmethemoglobinemia
‡A
Kinetic studies on the oxidation of oxyhemoglobin by biologically active iron thiosemicarbazone complexes: relevance to iron-chelator-induced methemoglobinemia.
‡9
1
|
|
919
|
|
|
‡a
ironingouttheroleofthecyclindependentkinaseinhibitorp21incancernovelironchelatingagentstotargetp21expressionandactivity
‡A
Ironing out the role of the cyclin-dependent kinase inhibitor, p21 in cancer: Novel iron chelating agents to target p21 expression and activity.
‡9
1
|
|
919
|
|
|
‡a
ironuptakeandmetabolisminthenewmillennium
‡A
Iron uptake and metabolism in the new millennium.
‡9
1
|
|
919
|
|
|
‡a
irontraffickinginthemitochondrionnovelpathwaysrevealedbydisease
‡A
Iron trafficking in the mitochondrion: novel pathways revealed by disease.
‡9
1
|
|
919
|
|
|
‡a
ironexportthroughthetransporterferroportin1ismodulatedbytheironchaperonepcbp2
‡A
Iron Export through the Transporter Ferroportin 1 Is Modulated by the Iron Chaperone PCBP2.
‡9
1
|
|
919
|
|
|
‡a
ironchelatorswithhighantiproliferativeactivityupregulatetheexpressionofagrowthinhibitoryandmetastasissuppressorgenealinkbetweenironmetabolismandproliferation
‡A
Iron chelators with high antiproliferative activity up-regulate the expression of a growth inhibitory and metastasis suppressor gene: a link between iron metabolism and proliferation
‡9
1
|
|
919
|
|
|
‡a
ironchelatorsofthedipyridylketonethiosemicarbazoneclassprecomplexationandtransmetalationeffectsonanticanceractivity
‡A
Iron chelators of the dipyridylketone thiosemicarbazone class: precomplexation and transmetalation effects on anticancer activity.
‡9
1
|
|
919
|
|
|
‡a
ironchelatorsofthe5012pyridylketonethiosemicarbazoneand2benzoylpyridinethiosemicarbazoneseriesinhibithiv1transcriptionidentificationofnovelcellulartargetsironcyclindependentkinasecdk2andcdk9
‡A
Iron chelators of the di-2-pyridylketone thiosemicarbazone and 2-benzoylpyridine thiosemicarbazone series inhibit HIV-1 transcription: identification of novel cellular targets--iron, cyclin-dependent kinase (CDK) 2, and CDK9
‡9
1
|
|
919
|
|
|
‡a
ironchelatorsforthetreatmentofironoverloaddiseaserelationshipbetweenstructureredoxactivityandtoxicity
‡A
Iron chelators for the treatment of iron overload disease: relationship between structure, redox activity, and toxicity.
‡9
1
|
|
919
|
|
|
‡a
ironchelatorsdevelopmentofnovelcompoundswithhighandselectiveantitumouractivity
‡A
Iron Chelators: Development of Novel Compounds with High and Selective Anti-Tumour Activity
‡9
1
|
|
919
|
|
|
‡a
ironchelatorsastherapeuticagentsforthetreatmentofcancer
‡A
Iron chelators as therapeutic agents for the treatment of cancer.
‡9
1
|
|
919
|
|
|
‡a
ironchelatormediatedalterationsingeneexpressionidentificationofnovelironregulatedmoleculesthataremoleculartargetsofhypoxiainduciblefactor1alphaandp53
‡A
Iron chelator-mediated alterations in gene expression: identification of novel iron-regulated molecules that are molecular targets of hypoxia-inducible factor-1 alpha and p53.
‡9
1
|
|
919
|
|
|
‡a
ironchelationregulatescyclind1expressionviatheproteasomealinktoirondeficiencymediatedgrowthsuppression
‡A
Iron chelation regulates cyclin D1 expression via the proteasome: a link to iron deficiency-mediated growth suppression
‡9
1
|
|
919
|
|
|
‡a
ironchelationinhibitionofkeysignalingpathwaysintheinductionoftheepithelialmesenchymaltransitioninpancreaticcancerandothertumors
‡A
Iron chelation: inhibition of key signaling pathways in the induction of the epithelial mesenchymal transition in pancreatic cancer and other tumors
‡9
1
|
|
919
|
|
|
‡a
ironchelationdecipheringnovelmoleculartargetsforcancertherapythetipoftheicebergofawebofironregulatedmolecules
‡A
Iron chelation: deciphering novel molecular targets for cancer therapy. The tip of the iceberg of a web of iron-regulated molecules
‡9
1
|
|
919
|
|
|
‡a
ironchelationbyclinicallyrelevantanthracyclinesalterationinexpressionofironregulatedgenesandatypicalchangesinintracellularirondistributionandtrafficking
‡A
Iron chelation by clinically relevant anthracyclines: alteration in expression of iron-regulated genes and atypical changes in intracellular iron distribution and trafficking.
‡9
1
|
|
919
|
|
|
‡a
ironchelationandregulationofthecellcycle2mechanismsofposttranscriptionalregulationoftheuniversalcyclindependentkinaseinhibitorp21cip1waf1byirondepletion
‡A
Iron chelation and regulation of the cell cycle: 2 mechanisms of posttranscriptional regulation of the universal cyclin-dependent kinase inhibitor p21CIP1/WAF1 by iron depletion
‡9
1
|
|
919
|
|
|
‡a
ironcatalysedassemblyofanasymmetricmixedligandtriplehelicate
‡A
Iron catalysed assembly of an asymmetric mixed-ligand triple helicate
‡9
1
|
|
919
|
|
|
‡a
ironandneoplasiaserumtransferrinreceptorandferritininprostatecancer
‡A
Iron and neoplasia: serum transferrin receptor and ferritin in prostate cancer
‡9
1
|
|
919
|
|
|
‡a
ironandgalliumincreaseironuptakefromtransferrinbyhumanmelanomacellsfurtherexaminationoftheferricammoniumcitrateactivatedironuptakeprocess
‡A
Iron and gallium increase iron uptake from transferrin by human melanoma cells: further examination of the ferric ammonium citrate-activated iron uptake process
‡9
1
|
|
919
|
|
|
‡a
investigationofsubstituted6aminohexanoatesasskinpenetrationenhancers
‡A
Investigation of substituted 6-aminohexanoates as skin penetration enhancers
‡9
1
|
|
919
|
|
|
‡a
investigatingthespectrumofbiologicalactivityofringsubstitutedsalicylanilidesandcarbamoylphenylcarbamates
‡A
Investigating the spectrum of biological activity of ring-substituted salicylanilides and carbamoylphenylcarbamates.
‡9
1
|
|
919
|
|
|
‡a
investigatingtheantiproliferativeactivityofquinoline58dionesandstyrylquinolinecarboxylicacidsontumorcelllines
‡A
Investigating the antiproliferative activity of quinoline-5,8-diones and styrylquinolinecarboxylic acids on tumor cell lines.
‡9
1
|
|
919
|
|
|
‡a
investigatingtheantiproliferativeactivityofstyrylazanaphthalenesandazanaphthalenediones
‡A
Investigating the anti-proliferative activity of styrylazanaphthalenes and azanaphthalenediones
‡9
1
|
|
919
|
|
|
‡a
investigatingtheactivityof2substitutedalkyl625dioxopyrrolidin1ylhexanoatesasskinpenetrationenhancers
‡A
Investigating the activity of 2-substituted alkyl-6-(2,5-dioxopyrrolidin-1-yl)hexanoates as skin penetration enhancers
‡9
1
|
|
919
|
|
|
‡a
investigatingbiologicalactivityspectrumfornovelquinolineanalogues
‡A
Investigating biological activity spectrum for novel quinoline analogues
‡9
1
|
|
919
|
|
|
‡a
interplayoftheironregulatedmetastasissuppressorndrg1withepidermalgrowthfactorreceptoregfrandoncogenicsignaling
‡A
Interplay of the iron-regulated metastasis suppressor NDRG1 with epidermal growth factor receptor (EGFR) and oncogenic signaling.
‡9
1
|
|
919
|
|
|
‡a
interplayoftheironregulatedmetastasissuppressorndrg1withepidermalgrowthfactorreceptor
‡A
Interplay of the iron-regulated metastasis suppressor NDRG1 with epidermal growth factor receptor
‡9
1
|
|
919
|
|
|
‡a
interferongammaandlipopolysaccharideregulatetheexpressionofnramp2andincreasetheuptakeofironfromlowrelativemolecularmasscomplexesbymacrophages
‡A
Interferon-gamma and lipopolysaccharide regulate the expression of Nramp2 and increase the uptake of iron from low relative molecular mass complexes by macrophages
‡9
1
|
|
919
|
|
|
‡a
invitrocharacterizationofthepharmacologicalpropertiesoftheanticancerchelatorbp4etanditsphase1metabolites
‡A
In Vitro Characterization of the Pharmacological Properties of the Anti-Cancer Chelator, Bp4eT, and Its Phase I Metabolites
‡9
1
|
|
919
|
|
|
‡a
identificationofnonferritinmitochondrialirondepositsinamousemodeloffriedreichataxia
‡A
Identification of nonferritin mitochondrial iron deposits in a mouse model of Friedreich ataxia
‡9
1
|
|
919
|
|
|
‡a
metastasissuppressorndrg1inhibitsstemnessofcolorectalcancerviadownregulationofnuclearβcateninandcd44
‡A
The metastasis suppressor, NDRG1, inhibits "stemness" of colorectal cancer via down-regulation of nuclear β-catenin and CD44.
‡9
1
|
|
919
|
|
|
‡a
metastasissuppressorndrg1modulatesthephosphorylationandnucleartranslocationofβcateninthroughmechanismsinvolvingfrat1andpak4
‡A
The metastasis suppressor NDRG1 modulates the phosphorylation and nuclear translocation of β-catenin through mechanisms involving FRAT1 and PAK4.
‡9
1
|
|
919
|
|
|
‡a
molecularmechanismsofthemetabolismandtransportofironinnormalandneoplasticcells
‡A
The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cells
‡9
1
|
|
919
|
|
|
‡a
nitricoxideironinterplayinmammaliancellstransportandstorageofdinitrosylironcomplexes
‡A
The nitric oxide-iron interplay in mammalian cells: transport and storage of dinitrosyl iron complexes.
‡9
1
|
|
919
|
|
|
‡a
novelironchelator2pyridylcarboxaldehyde2thiophenecarboxylhydrazonereducescatecholaminemediatedmyocardialtoxicity
‡A
The novel iron chelator, 2-pyridylcarboxaldehyde 2-thiophenecarboxyl hydrazone, reduces catecholamine-mediated myocardial toxicity
‡9
1
|
|
919
|
|
|
‡a
novelthiosemicarbazone5012pyridylketone4cyclohexyl4methyl3thiosemicarbazonedpcinhibitsneuroblastomagrowthinvitroandinvivoviamultiplemechanisms
‡A
The novel thiosemicarbazone, di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone (DpC), inhibits neuroblastoma growth in vitro and in vivo via multiple mechanisms.
‡9
1
|
|
919
|
|
|
‡a
oldandnewbiochemistryofpolyamines
‡A
The old and new biochemistry of polyamines
‡9
1
|
|
919
|
|
|
‡a
potentandnovelthiosemicarbazonechelators5012pyridylketone44dimethyl3thiosemicarbazoneand2benzoylpyridine44dimethyl3thiosemicarbazoneaffectcrucialthiolsystemsrequiredforribonucleotidereductaseactivity
‡A
The potent and novel thiosemicarbazone chelators di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone and 2-benzoylpyridine-4,4-dimethyl-3-thiosemicarbazone affect crucial thiol systems required for ribonucleotide reductase activity.
‡9
1
|
|
919
|
|
|
‡a
potentialofironchelatorsofthepyridoxalisonicotinoylhydrazoneclassaseffectiveantiproliferativeagents4themechanismsinvolvedininhibitingcellcycleprogression
‡A
The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents, IV: The mechanisms involved in inhibiting cell-cycle progression
‡9
1
|
|
919
|
|
|
‡a
identificationofinvitrometabolitesofthenovelantitumorthiosemicarbazonedpcusingultrahighperformanceliquidchromatographyquadrupoletimeofflightmassspectrometry
‡A
Identification of in vitro metabolites of the novel anti-tumor thiosemicarbazone, DpC, using ultra-high performance liquid chromatography–quadrupole-time-of-flight mass spectrometry
‡9
1
|
|
919
|
|
|
‡a
identificationofdistinctchangesingeneexpressionaftermodulationofmelanomatumorantigenp97melanotransferrininmultiplemodelsinvitroandinvivo
‡A
Identification of distinct changes in gene expression after modulation of melanoma tumor antigen p97 (melanotransferrin) in multiple models in vitro and in vivo
‡9
1
|
|
919
|
|
|
‡a
redoxactiveanticancerdrugdp44mtinhibitstcellactivationandcd25throughacopperdependentmechanism
‡A
The redox-active, anti-cancer drug Dp44mT inhibits T-cell activation and CD25 through a copper-dependent mechanism.
‡9
1
|
|
919
|
|
|
‡a
releaseofironandtransferrinfromthehumanmelanomacell
‡A
The release of iron and transferrin from the human melanoma cell
‡9
1
|
|
919
|
|
|
‡a
identificationofdifferentialphosphorylationandsubcellularlocalizationofthemetastasissuppressorndrg1
‡A
Identification of differential phosphorylation and sub-cellular localization of the metastasis suppressor, NDRG1.
‡9
1
|
|
919
|
|
|
‡a
identificationofdifferentialantineoplasticactivityofcopperbisthiosemicarbazonesthatismediatedbyintracellularreactiveoxygenspeciesgenerationandlysosomalmembranepermeabilization
‡A
Identification of differential anti-neoplastic activity of copper bis(thiosemicarbazones) that is mediated by intracellular reactive oxygen species generation and lysosomal membrane permeabilization
‡9
1
|
|
919
|
|
|
‡a
renaissanceofpolypharmacologyinthedevelopmentofanticancertherapeuticsinhibitionofthetriadofdeathincancerby5012pyridylketonethiosemicarbazones
‡A
The renaissance of polypharmacology in the development of anti-cancer therapeutics: Inhibition of the "Triad of Death" in cancer by Di-2-pyridylketone thiosemicarbazones.
‡9
1
|
|
919
|
|
|
‡a
roleofhypoxiaandnitrogenmonoxideintheregulationofcellularironmetabolism
‡A
The role of hypoxia and nitrogen monoxide in the regulation of cellular iron metabolism.
‡9
1
|
|
919
|
|
|
‡a
identificationofamechanismofironuptakebycellswhichisstimulatedbyhydroxylradicalsgeneratedviatheironcatalysedhaberweissreaction
‡A
Identification of a mechanism of iron uptake by cells which is stimulated by hydroxyl radicals generated via the iron-catalysed Haber-Weiss reaction
‡9
1
|
|
919
|
|
|
‡a
identificationandcharacterizationofthiosemicarbazoneswithantifungalandantitumoreffectscellularironchelationmediatingcytotoxicactivity
‡A
Identification and characterization of thiosemicarbazones with antifungal and antitumor effects: cellular iron chelation mediating cytotoxic activity.
‡9
1
|
|
919
|
|
|
‡a
roleofndrg1inthepathologyandpotentialtreatmentofhumancancers
‡A
The role of NDRG1 in the pathology and potential treatment of human cancers
‡9
1
|
|
919
|
|
|
‡a
roleoftheantioxidantresponseinmitochondrialdysfunctionindegenerativediseasescrosstalkbetweenantioxidantdefenseautophagyandapoptosis
‡A
The Role of the Antioxidant Response in Mitochondrial Dysfunction in Degenerative Diseases: Cross-Talk between Antioxidant Defense, Autophagy, and Apoptosis
‡9
1
|
|
919
|
|
|
‡a
hydrazonechelatorsforthetreatmentofironoverloaddisordersironcoordinationchemistryandbiologicalactivity
‡A
Hydrazone chelators for the treatment of iron overload disorders: iron coordination chemistry and biological activity
‡9
1
|
|
919
|
|
|
‡a
hplcmethodsfordeterminationof2novelthiosemicarbazoneanticancerdrugsn4mtanddp44mtinplasmaandtheirapplicationtoinvitroplasmastabilityoftheseagents
‡A
HPLC methods for determination of two novel thiosemicarbazone anti-cancer drugs (N4mT and Dp44mT) in plasma and their application to in vitro plasma stability of these agents
‡9
1
|
|
919
|
|
|
‡a
tgfbetapi3kaktandptenpathwaysestablishedandproposedbiochemicalintegrationinprostatecancer
‡A
The TGF-beta, PI3K/Akt and PTEN pathways: established and proposed biochemical integration in prostate cancer
‡9
1
|
|
919
|
|
|
‡a
transferrinhomologuemelanotransferrinp97israpidlycatabolizedbytheliveroftheratanddoesnoteffectivelydonateirontothebrain
‡A
The transferrin homologue, melanotransferrin (p97), is rapidly catabolized by the liver of the rat and does not effectively donate iron to the brain
‡9
1
|
|
919
|
|
|
‡a
hplcmethodsfordeterminationof2novelthiosemicarbazoneanticancerdrugs
‡A
HPLC methods for determination of two novel thiosemicarbazone anti-cancer drugs
‡9
1
|
|
919
|
|
|
‡a
heterocyclicdithiocarbazateironchelatorsfecoordinationchemistryandbiologicalactivity
‡A
Heterocyclic dithiocarbazate iron chelators: Fe coordination chemistry and biological activity.
‡9
1
|
|
919
|
|
|
‡a
translationalregulatoreif3athetrickyeif3subunit
‡A
The translational regulator eIF3a: the tricky eIF3 subunit!
‡9
1
|
|
919
|
|
|
‡a
uptakeofinorganicironcomplexesbyhumanmelanomacells
‡A
The uptake of inorganic iron complexes by human melanoma cells
‡9
1
|
|
919
|
|
|
‡a
hepcidinthehormoneofironmetabolismisboundspecificallytoalpha2macroglobulininblood
‡A
Hepcidin, the hormone of iron metabolism, is bound specifically to alpha-2-macroglobulin in blood.
‡9
1
|
|
919
|
|
|
‡a
hepcidinshowsomeselfcontrolhowthehormoneofironmetabolismregulatesitsownexpression
‡A
Hepcidin, show some self-control! How the hormone of iron metabolism regulates its own expression.
‡9
1
|
|
919
|
|
|
‡a
uptakeofironandtransferrinbythehumanmalignantmelanomacell
‡A
The uptake of iron and transferrin by the human malignant melanoma cell
‡9
1
|
|
919
|
|
|
‡a
useofironchelatorsinbiocidalcompositionsevaluationofpatentwo2014059417a1
‡A
The use of iron chelators in biocidal compositions: evaluation of patent, WO2014059417A1
‡9
1
|
|
919
|
|
|
‡a
halogenated2benzoylpyridinethiosemicarbazonexbptchelatorswithpotentandselectiveantineoplasticactivityrelationshiptointracellularredoxactivity
‡A
Halogenated 2'-benzoylpyridine thiosemicarbazone (XBpT) chelators with potent and selective anti-neoplastic activity: relationship to intracellular redox activity
‡9
1
|
|
919
|
|
|
‡a
halogenated2benzoylpyridinethiosemicarbazone
‡A
Halogenated 2'-benzoylpyridine thiosemicarbazone
‡9
1
|
|
919
|
|
|
‡a
thiosemicarbazonesfromtheoldtonewironchelatorsthataremorethanjustribonucleotidereductaseinhibitors
‡A
Thiosemicarbazones from the old to new: iron chelators that are more than just ribonucleotide reductase inhibitors.
‡9
1
|
|
919
|
|
|
‡a
thiosemicarbazonesthenewwaveincancertreatment
‡A
Thiosemicarbazones: the new wave in cancer treatment
‡9
1
|
|
919
|
|
|
‡a
growthofhumantumorcelllinesintransferrinfreelowironmedium
‡A
Growth of human tumor cell lines in transferrin-free, low-iron medium
‡9
1
|
|
919
|
|
|
‡a
transcriptionalregulationofthecyclindependentkinaseinhibitorp21cip1waf1bythechelatordp44mt
‡A
Transcriptional regulation of the cyclin-dependent kinase inhibitor, p21CIP1/WAF1, by the chelator, Dp44mT.
‡9
1
|
|
919
|
|
|
‡a
tumorstressorsinduce2mechanismsofintracellularpglycoproteinmediatedresistancethatareovercomebylysosomaltargetedthiosemicarbazones
‡A
Tumor stressors induce two mechanisms of intracellular p-glycoprotein-mediated resistance that are overcome by lysosomal-targeted thiosemicarbazones.
‡9
1
|
|
919
|
|
|
‡a
growtharrestanddnadamage45alphagadd45alpha
‡A
Growth arrest and DNA damage-45 alpha (GADD45alpha).
‡9
1
|
|
919
|
|
|
‡a
growtharrestanddnadamage45alpha
‡A
Growth arrest and DNA damage-45 alpha
‡9
1
|
|
919
|
|
|
‡a
tuningtheantiproliferativeactivityofbiologicallyactiveironchelatorscharacterizationofthecoordinationchemistryandbiologicalefficacyof2acetylpyridineand2benzoylpyridinehydrazoneligands
‡A
Tuning the antiproliferative activity of biologically active iron chelators: characterization of the coordination chemistry and biological efficacy of 2-acetylpyridine and 2-benzoylpyridine hydrazone ligands
‡9
1
|
|
919
|
|
|
‡a
turningthegunoncancerutilizinglysosomalpglycoproteinasanewstrategytoovercomemultidrugresistance
‡A
Turning the gun on cancer: Utilizing lysosomal P-glycoprotein as a new strategy to overcome multi-drug resistance.
‡9
1
|
|
919
|
|
|
‡a
2saturablemechanismsofironuptakefromtransferrininhumanmelanomacellstheeffectoftransferrinconcentrationchelatorsandmetabolicprobesontransferrinandironuptake
‡A
Two saturable mechanisms of iron uptake from transferrin in human melanoma cells: the effect of transferrin concentration, chelators, and metabolic probes on transferrin and iron uptake
‡9
1
|
|
919
|
|
|
‡a
unexpectedanthracyclinemediatedalterationsinironregulatoryproteinrnabindingactivitytheironandcoppercomplexesofanthracyclinesdecreasernabindingactivity
‡A
Unexpected anthracycline-mediated alterations in iron-regulatory protein-RNA-binding activity: the iron and copper complexes of anthracyclines decrease RNA-binding activity
‡9
1
|
|
919
|
|
|
‡a
unprecedentedoxidationofabiologicallyactivearoylhydrazonechelatorcatalysedbyiron
‡A
Unprecedented oxidation of a biologically active aroylhydrazone chelator catalysed by iron
‡9
1
|
|
919
|
|
|
‡a
unprecedentedoxidationofabiologicallyactivearoylhydrazonechelatorcatalysedbyiron3serendipitousidentificationofdiacylhydrazineligandswithhighironchelationefficacy
‡A
Unprecedented oxidation of a biologically active aroylhydrazone chelator catalysed by iron(III): serendipitous identification of diacylhydrazine ligands with high iron chelation efficacy
‡9
1
|
|
919
|
|
|
‡a
unravelingthemysteriesofserumalbuminmorethanjustaserumprotein
‡A
Unraveling the mysteries of serum albumin-more than just a serum protein.
‡9
1
|
|
919
|
|
|
‡a
zinc2thiosemicarbazonecomplexesarelocalizedtothelysosomalcompartmentwheretheytransmetallatewithcopperionstoinducecytotoxicity
‡A
Zinc(II)-Thiosemicarbazone Complexes Are Localized to the Lysosomal Compartment Where They Transmetallate with Copper Ions to Induce Cytotoxicity.
‡9
1
|
|
919
|
|
|
‡a
glucosemodulationinducesreactiveoxygenspeciesandincreasespglycoproteinmediatedmultidrugresistancetochemotherapeutics
‡A
Glucose modulation induces reactive oxygen species and increases P-glycoprotein-mediated multidrug resistance to chemotherapeutics.
‡9
1
|
|
919
|
|
|
‡a
glucosemodulationinduceslysosomeformationandincreaseslysosomotropicdrugsequestrationviathepglycoproteindrugtransporter
‡A
Glucose Modulation Induces Lysosome Formation and Increases Lysosomotropic Drug Sequestration via the P-Glycoprotein Drug Transporter.
‡9
1
|
|
919
|
|
|
‡a
generationandcharacterizationoftransgenicmicehyperexpressingmelanomatumourantigenp97melanotransferrinnoovertalterationinphenotype
‡A
Generation and characterization of transgenic mice hyper-expressing melanoma tumour antigen p97 (Melanotransferrin): no overt alteration in phenotype.
‡9
1
|
|
919
|
|
|
‡a
generationandcharacterizationoftransgenicmicehyperexpressingmelanomatumourantigenp97
‡A
Generation and characterization of transgenic mice hyper-expressing melanoma tumour antigen p97
‡9
1
|
|
919
|
|
|
‡a
geneofthemonthinterleukin6il6
‡A
Gene of the month: Interleukin 6 (IL-6).
‡9
1
|
|
919
|
|
|
‡a
geneofthemonthbecn1
‡A
Gene of the month: BECN1.
‡9
1
|
|
919
|
|
|
‡a
geneofthemonthampkinaseprkaa1
‡A
Gene of the month. AMP kinase (PRKAA1).
‡9
1
|
|
919
|
|
|
‡a
futureoftoxicologyironchelatorsanddifferingmodesofactionandtoxicitythechangingfaceofironchelationtherapy
‡A
Future of toxicology--iron chelators and differing modes of action and toxicity: the changing face of iron chelation therapy
‡9
1
|
|
919
|
|
|
‡a
frataxinitsroleinironmetabolismandthepathogenesisoffriedreichsataxia
‡A
Frataxin: its role in iron metabolism and the pathogenesis of Friedreich's ataxia.
‡9
1
|
|
919
|
|
|
‡a
frataxinandthemolecularmechanismofmitochondrialironloadinginfriedreichsataxia
‡A
Frataxin and the molecular mechanism of mitochondrial iron-loading in Friedreich's ataxia
‡9
1
|
|
919
|
|
|
‡a
frataxinamoleculeofmysterytradingstabilityforfunctioninitsironbindingsite
‡A
Frataxin, a molecule of mystery: trading stability for function in its iron-binding site
‡9
1
|
|
919
|
|
|
‡a
4cytotoxicn4substitutedthiosemicarbazonesderivedfrom2hydroxynaphthalene1carboxaldehyde
‡A
Four cytotoxic N4-substituted thiosemicarbazones derived from 2-hydroxynaphthalene-1-carboxaldehyde
‡9
1
|
|
919
|
|
|
‡a
fixingfrataxinironingoutthemetabolicdefectinfriedreichsataxia
‡A
Fixing frataxin: 'ironing out' the metabolic defect in Friedreich's ataxia
‡9
1
|
|
919
|
|
|
‡a
exploringtheanticanceractivityofnovelthiosemicarbazonesgeneratedthroughthecombinationofretrofragmentsdissectionofcriticalstructureactivityrelationships
‡A
Exploring the anti-cancer activity of novel thiosemicarbazones generated through the combination of retro-fragments: dissection of critical structure-activity relationships
‡9
1
|
|
919
|
|
|
‡a
exploitingcancermetalmetabolismusinganticancermetalbindingagents
‡A
Exploiting Cancer Metal Metabolism using Anti-Cancer Metal-Binding Agents.
‡9
1
|
|
919
|
|
|
‡a
expandinghorizonsinironchelationandthetreatmentofcancerroleofironintheregulationoferstressandtheepithelialmesenchymaltransition
‡A
Expanding horizons in iron chelation and the treatment of cancer: role of iron in the regulation of ER stress and the epithelial-mesenchymal transition.
‡9
1
|
|
919
|
|
|
‡a
examinationofthemechanismsinvolvedindoxorubicinmediatedironaccumulationinferritinstudiesusingmetabolicinhibitorsproteinsynthesisinhibitorsandlysosomotropicagents
‡A
Examination of the mechanism(s) involved in doxorubicin-mediated iron accumulation in ferritin: studies using metabolic inhibitors, protein synthesis inhibitors, and lysosomotropic agents
‡9
1
|
|
919
|
|
|
‡a
examinationofthemechanismofactionofnitrogenmonoxideonironuptakefromtransferrin
‡A
Examination of the mechanism of action of nitrogen monoxide on iron uptake from transferrin
‡9
1
|
|
919
|
|
|
‡a
examinationofthedistributionofthetransferrinhomologuemelanotransferrintumourantigenp97inmouseandhuman
‡A
Examination of the distribution of the transferrin homologue, melanotransferrin (tumour antigen p97), in mouse and human.
‡9
1
|
|
919
|
|
|
‡a
erythroiddifferentiationandprotoporphyrin9downregulatefrataxinexpressioninfriendcellscharacterizationoffrataxinexpressioncomparedtomoleculesinvolvedinironmetabolismandhemoglobinization
‡A
Erythroid differentiation and protoporphyrin IX down-regulate frataxin expression in Friend cells: characterization of frataxin expression compared to molecules involved in iron metabolism and hemoglobinization
‡9
1
|
|
919
|
|
|
‡a
erp29inducesbreastcancercellgrowtharrestandsurvivalthroughmodulationofactivationofp38andupregulationoferstressproteinp58ipk
‡A
ERp29 induces breast cancer cell growth arrest and survival through modulation of activation of p38 and upregulation of ER stress protein p58IPK
‡9
1
|
|
919
|
|
|
‡a
endoplasmicreticulumprotein29regulatesepithelialcellintegrityduringthemesenchymalepithelialtransitioninbreastcancercells
‡A
Endoplasmic reticulum protein 29 regulates epithelial cell integrity during the mesenchymal-epithelial transition in breast cancer cells
‡9
1
|
|
919
|
|
|
‡a
endoplasmicreticulumprotein29erp29anemergingroleincancer
‡A
Endoplasmic reticulum protein 29 (ERp29): An emerging role in cancer
‡9
1
|
|
919
|
|
|
‡a
endoplasmicreticulumprotein29
‡A
Endoplasmic reticulum protein 29
‡9
1
|
|
919
|
|
|
‡a
elucidationofthemechanismofmitochondrialironloadinginfriedreichsataxiabyanalysisofamousemutant
‡A
Elucidation of the mechanism of mitochondrial iron loading in Friedreich's ataxia by analysis of a mouse mutant
‡9
1
|
|
919
|
|
|
‡a
effectsofnitrogenmonoxideandcarbonmonoxideonmolecularandcellularironmetabolismmirrorimageeffectormoleculesthattargetiron
‡A
Effects of nitrogen monoxide and carbon monoxide on molecular and cellular iron metabolism: mirror-image effector molecules that target iron
‡9
1
|
|
919
|
|
|
‡a
effectofthepiperazineunitandmetalbindingsitepositiononthesolubilityandantiproliferativeactivityofruthenium2andosmium2arenecomplexesofisomericindoloquinolinepiperazinehybrids
‡A
Effect of the piperazine unit and metal-binding site position on the solubility and anti-proliferative activity of ruthenium(II)- and osmium(II)- arene complexes of isomeric indolo[3,2-c]quinoline-piperazine hybrids.
‡9
1
|
|
919
|
|
|
‡a
effectofpyridoxalisonicotinoylhydrazoneandotherhydrazonesonironreleasefrommacrophagesreticulocytesandhepatocytes
‡A
Effect of pyridoxal isonicotinoyl hydrazone and other hydrazones on iron release from macrophages, reticulocytes and hepatocytes
‡9
1
|
|
919
|
|
|
‡a
duodenalcytochromebdcytbinironmetabolismanupdateonfunctionandregulation
‡A
Duodenal cytochrome b (DCYTB) in iron metabolism: an update on function and regulation.
‡9
1
|
|
919
|
|
|
‡a
dp44mttargetstheakttgfβanderkpathwaysviathemetastasissuppressorndrg1innormalprostateepithelialcellsandprostatecancercells
‡A
Dp44mT targets the AKT, TGF-β and ERK pathways via the metastasis suppressor NDRG1 in normal prostate epithelial cells and prostate cancer cells.
‡9
1
|
|
919
|
|
|
‡a
doesfreeextracellularironexistinhaemochromatosisandotherpathologiesandisitredoxactive
‡A
Does free extracellular iron exist in haemochromatosis and other pathologies, and is it redox active?
‡9
1
|
|
919
|
|
|
‡a
dipyridylthiosemicarbazonechelatorswithpotentandselectiveantitumoractivityformironcomplexeswithredoxactivity
‡A
Dipyridyl Thiosemicarbazone Chelators with Potent and Selective Antitumor Activity Form Iron Complexes with Redox Activity
‡9
1
|
|
919
|
|
|
‡a
differentialtargetingofthecyclindependentkinaseinhibitorp21cip1waf1bychelatorswithantiproliferativeactivityinarangeoftumorcelltypes
‡A
Differential targeting of the cyclin-dependent kinase inhibitor, p21CIP1/WAF1, by chelators with anti-proliferative activity in a range of tumor cell-types
‡9
1
|
|
919
|
|
|
‡a
differentialregulationofthemenkesandwilsondiseasecoppertransportersbyhormonesanintegratedmodelofmetaltransportintheplacenta
‡A
Differential regulation of the Menkes and Wilson disease copper transporters by hormones: an integrated model of metal transport in the placenta
‡9
1
|
|
919
|
|
|
‡a
differentialeffectsoncellularironmetabolismofthephysiologicallyrelevantdiatomiceffectormoleculesnoandcothatbindiron
‡A
Differential effects on cellular iron metabolism of the physiologically relevant diatomic effector molecules, NO and CO, that bind iron
‡9
1
|
|
919
|
|
|
‡a
5012pyridylketone44dimethyl3thiosemicarbazonedp44mtovercomesmultidrugresistancebyanovelmechanisminvolvingthehijackingoflysosomalpglycoproteinpgp
‡A
Di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT) overcomes multidrug resistance by a novel mechanism involving the hijacking of lysosomal P-glycoprotein (Pgp).
‡9
1
|
|
919
|
|
|
‡a
developmentofpotentialironchelatorsforthetreatmentoffriedreichsataxialigandsthatmobilizemitochondrialiron
‡A
Development of potential iron chelators for the treatment of Friedreich's ataxia: ligands that mobilize mitochondrial iron
‡9
1
|
|
919
|
|
|
‡a
developmentofnovelaroylhydrazoneligandsforironchelationtherapy2pyridylcarboxaldehydeisonicotinoylhydrazoneanalogs
‡A
Development of novel aroylhydrazone ligands for iron chelation therapy: 2-pyridylcarboxaldehyde isonicotinoyl hydrazone analogs
‡9
1
|
|
919
|
|
|
‡a
developmentofironchelatorstotreatironoverloaddiseaseandtheiruseasexperimentaltoolstoprobeintracellularironmetabolism
‡A
Development of iron chelators to treat iron overload disease and their use as experimental tools to probe intracellular iron metabolism
‡9
1
|
|
919
|
|
|
‡a
developmentofanlcmsmsmethodforanalysisofinterconvertiblezeisomersofthenovelanticanceragentbp4et
‡A
Development of an LC-MS/MS method for analysis of interconvertible Z/E isomers of the novel anticancer agent, Bp4eT.
‡9
1
|
|
919
|
|
|
‡a
developmentandvalidationofhplcdadmethodsfortheanalysisof2novelironchelatorswithpotentanticanceractivity
‡A
Development and validation of HPLC-DAD methods for the analysis of two novel iron chelators with potent anti-cancer activity
‡9
1
|
|
919
|
|
|
‡a
designsynthesisandcharacterizationofnovelironchelatorsstructureactivityrelationshipsofthe2benzoylpyridinethiosemicarbazoneseriesandtheir3nitrobenzoylanaloguesaspotentantitumoragents
‡A
Design, synthesis, and characterization of novel iron chelators: structure-activity relationships of the 2-benzoylpyridine thiosemicarbazone series and their 3-nitrobenzoyl analogues as potent antitumor agents.
‡9
1
|
|
919
|
|
|
‡a
designsynthesisandcharacterizationofnewironchelatorswithantiproliferativeactivitystructureactivityrelationshipsofnovelthiohydrazoneanalogues
‡A
Design, synthesis, and characterization of new iron chelators with anti-proliferative activity: structure-activity relationships of novel thiohydrazone analogues.
‡9
1
|
|
919
|
|
|
‡a
deferipronegreaterefficacyatdepletingmyocardialthanhepaticiron
‡A
Deferiprone: greater efficacy at depleting myocardial than hepatic iron?
‡9
1
|
|
919
|
|
|
‡a
cytotoxicironchelatorscharacterizationofthestructuresolutionchemistryandredoxactivityofligandsandironcomplexesofthe5012pyridylketoneisonicotinoylhydrazonehpkihanalogues
‡A
Cytotoxic iron chelators: characterization of the structure, solution chemistry and redox activity of ligands and iron complexes of the di-2-pyridyl ketone isonicotinoyl hydrazone (HPKIH) analogues
‡9
1
|
|
919
|
|
|
‡a
cytosolicphospholipasea2αsustainspaktperkandarlevelsinptennullmutatedprostatecancercells
‡A
Cytosolic phospholipase A2α sustains pAKT, pERK and AR levels in PTEN-null/mutated prostate cancer cells
‡9
1
|
|
919
|
|
|
‡a
crystalandmolecularstructureof2hydroxy1naphthaldehydeisonicotinoylhydrazonenihanditsiron3complexanironchelatorwithantitumouractivity
‡A
Crystal and molecular structure of 2-hydroxy-1-naphthaldehyde isonicotinoyl hydrazone (NIH) and its iron(III) complex: an iron chelator with anti-tumour activity
‡9
1
|
|
919
|
|
|
‡a
couplingofthepolyamineandironmetabolismpathwaysintheregulationofproliferationmechanisticlinkstoalterationsinkeypolyaminebiosyntheticandcatabolicenzymes
‡A
Coupling of the polyamine and iron metabolism pathways in the regulation of proliferation: Mechanistic links to alterations in key polyamine biosynthetic and catabolic enzymes
‡9
1
|
|
919
|
|
|
‡a
correctionnmycdownstreamregulated1ndrg1isregulatedbyeukaryoticinitiationfactor3aeif3aduringcellularstresscausedbyirondepletion
‡A
Correction: N-myc Downstream Regulated 1 (NDRG1) Is Regulated by Eukaryotic Initiation Factor 3a (eIF3a) during Cellular Stress Caused by Iron Depletion
‡9
1
|
|
919
|
|
|
‡a
correctionnmycdownstreamregulated1
‡A
Correction: N-myc Downstream Regulated 1
‡9
1
|
|
919
|
|
|
‡a
copperthatcancerwithlysosomallove
‡A
Copper that cancer with lysosomal love!
‡9
1
|
|
919
|
|
|
‡a
copperandconquercoppercomplexesof5012pyridylketonethiosemicarbazonesasnovelanticancertherapeutics
‡A
Copper and conquer: copper complexes of di-2-pyridylketone thiosemicarbazones as novel anti-cancer therapeutics.
‡9
1
|
|
919
|
|
|
‡a
conjugatesofdesferrioxaminebdfobwithderivativesofadamantaneorwithorallyavailablechelatorsaspotentialagentsfortreatingironoverload
‡A
Conjugates of desferrioxamine B (DFOB) with derivatives of adamantane or with orally available chelators as potential agents for treating iron overload
‡9
1
|
|
919
|
|
|
‡a
conjugatesofdesferrioxamineb
‡A
Conjugates of desferrioxamine B
‡9
1
|
|
946
|
|
|
‡a
b
‡9
1
|
|
996
|
|
|
‡2
NUKAT|n 2018082069
|
|
996
|
|
|
‡2
LC|no2013038517
|
|
996
|
|
|
‡2
LC|no2012142428
|
|
996
|
|
|
‡2
N6I|vtls000005382
|
|
996
|
|
|
‡2
ISNI|0000000030512382
|
|
996
|
|
|
‡2
RERO|A006312394
|
|
996
|
|
|
‡2
LC|n 78005745
|
|
996
|
|
|
‡2
LC|nr2006011118
|
|
996
|
|
|
‡2
BIBSYS|90233440
|
|
996
|
|
|
‡2
SUDOC|099130823
|
|
996
|
|
|
‡2
NUKAT|n 96639587
|
|
996
|
|
|
‡2
LC|nr 95018362
|
|
996
|
|
|
‡2
NTA|252000730
|
|
996
|
|
|
‡2
ISNI|0000000032897247
|
|
996
|
|
|
‡2
BIBSYS|90156616
|
|
996
|
|
|
‡2
ISNI|0000000035761599
|
|
996
|
|
|
‡2
LC|n 79003147
|
|
996
|
|
|
‡2
LC|n 80011187
|
|
996
|
|
|
‡2
NII|DA07252599
|
|
996
|
|
|
‡2
BIBSYS|90150720
|
|
996
|
|
|
‡2
RERO|A023966487
|
|
996
|
|
|
‡2
ISNI|0000000394143135
|
|
996
|
|
|
‡2
BIBSYS|3093358
|
|
996
|
|
|
‡2
CAOONL|ncf11213715
|
|
996
|
|
|
‡2
NTA|108618951
|
|
996
|
|
|
‡2
ISNI|0000000388195174
|
|
996
|
|
|
‡2
LC|n 89666360
|
|
996
|
|
|
‡2
CAOONL|ncf10408765
|
|
996
|
|
|
‡2
NTA|06759090X
|
|
996
|
|
|
‡2
LC|no2024101268
|
|
996
|
|
|
‡2
ISNI|0000000054424395
|
|
996
|
|
|
‡2
NTA|172314119
|
|
996
|
|
|
‡2
BIBSYS|90067458
|
|
996
|
|
|
‡2
ISNI|0000000034147116
|
|
996
|
|
|
‡2
J9U|987007391631405171
|
|
996
|
|
|
‡2
LC|n 95047152
|
|
996
|
|
|
‡2
SUDOC|274461986
|
|
997
|
|
|
‡a
1900 0 flourished 0000 0
‡9
1
|
